HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND): PERFORMANCE OF &#191;3 QUESTIONS TEST&#191; AS SCREENING TEST, PREVALENCE, CLINICAL CORRELATES AND THERAPEUTIC APPROACH IN THE SAN PAOLO INFECTIOUS DISEASES&#191; (SPID) COHORT. by F. Bai
UNIVERSITA’ DEGLI STUDI DI MILANO 
Dipartimento di Scienze della Salute 
Facoltà di Medicina e Chirurgia 
Scuola di Dottorato in Medicina Clinica e Sperimentale 
 
 
 
 
HIV-Associated Neurocognitive Disorders (HAND):  
performance of “3 Questions Test” as screening test,  
prevalence, clinical correlates and therapeutic approach  
in the San Paolo Infectious Diseases’ (SPID) cohort 
 
 
 
Tutor: Prof.ssa G.C. Marchetti 
Coordinatore del Dottorato: Prof.ssa A. d’Arminio Monforte 
 
 
 
 
Tesi di Dottorato di Ricerca – XXX ciclo 
Francesca Bai 
Matricola R10979 
 
 
Anno accademico 2016/2017 
 
Summary 
Summary ................................................................................................................................ 3 
Introduction ............................................................................................................................ 7 
Aim ...................................................................................................................................... 24 
Materials and methods .......................................................................................................... 27 
Results .................................................................................................................................. 31 
Performance of the “3 Questions Test” as a screening test of HIV-Associated 
Neurocognitive Disorders: evaluation of Sensitivity, Specificity, Positive and Negative 
Predictive Value and association with Altered Quality of Life (3QT study). ...................... 32 
Less severe HIV-Associated Neurocognitive Disorders (HAND) are still common among 
antiretroviral (cART)-naive and cART-treated people living with HIV: association with not 
Italian origin, unemployment and non AIDS-related comorbidities (NeuroHIV Study) ...... 41 
Clinical and viro-immunological correlates of HIV-Associated Neurocognitive Disorders in 
a cohort of antiretroviral-naive patients (CSF/plasma HIV-RNA ratio study) ..................... 48 
Peripheral and Cerebrospinal Fluid Immune Activation and Inflammation in Chronically 
HIV-Infected Patients Before and After Virally-Suppressive cART (Neuro MITO Study) . 52 
Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders: Case Reports 
of A New Computer-Based Restorative Approach In 3 HIV-Positive cART-Treated Patients
 ......................................................................................................................................... 64 
Conclusions .......................................................................................................................... 69 
Figures and tables ................................................................................................................. 72 
Bibliography ................................................................................................................... 120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Summary 
 
 
 
 
 
 
 
 
 
 
Background 
 
The prevalence of HIV-associated neurocognitive disorders (HAND) has not declined in 
recent years, except for most severe forms of dementia, and is estimated around 15-
55% of treated HIV-positive patients. A brief, easy-to-perform and standardized 
screening test for cognitive impairment in HIV-infected subjects is not yet available and 
current European AIDS Society (EACS) guidelines for HIV treatment suggest the use of 
“Three Questions Test” for the first approach. Moreover, the interaction between HIV 
and the brain is complex and poorly understood; the virus itself, immunological and toxic 
phenomena are implicated in the pathogenesis of cognitive disorders in HIV-infected 
patients. Several CSF and plasma biomarkers have been studied, but no one is suitable 
in clinical practice. Finally, combination antiretroviral therapy (cART) is effective only in 
a subset of patients and complementary treatments, as well as cognitive rehabilitation 
training, are needed. 
 
Aim 
 
To shed light on this topic, we conducted 5 studies with the following aims: 
- “Three Questions Test (3QT) study”: we aimed to explore the performance of the 
“Three Questions Test”, proposed by EACS guidelines for the screening of cognitive 
impairment in HIV-infected patients;  
- “NeuroHIV study” and “CSF/plasma HIV-RNA ratio study”: we investigated the 
prevalence, the clinical and viro-immunological correlates of HAND in a cohort of 
antiretroviral-naïve and cART-treated HIV-positive patients. We also studied the 
modification of HAND after at least 12 months of virological effective antiretroviral 
treatment; 
- “Neuro MITO study”: we explored a panel of plasma and CSF inflammatory and 
immune activation markers in naive HIV-infected patients and we studied the effects of 
12 months of virally-suppressive cART, according to CSF/plasma HIV-RNA ratio; 
- “Case report of cognitive rehabilitation”: we studied the efficacy of a new computer-
based program complementary to cART in improving cognitive functioning. 
 
Material and methods 
 
We enrolled antiretroviral-naive and cART-treated HIV-infected patients in active follow 
up at the SPID Cohort. Patients underwent a comprehensive neuropsychological 
evaluation by a trained neuropsychologist consisting of 11 tests exploring 7 main 
cognitive domains; the neuropsychological assessment included also the Instrumental Activities 
Of Daily Living (IADL), the Hospital Anxiety and Depression Scale (HADS) and the SF-
36 Health Survey (SF-36). Frascati’s criteria were used for the diagnosis of HAND. According to the 
study, blood sampling and lumbar puncture were performed to detect HIV-RNA and a 
panel of inflammation and immune activation markers. Statistical analyses were 
performed with SPSS software (version 21.0).  
 
Results 
 
- “3QT study”: we enrolled 191 antiretroviral-naive and 111 on treatment HIV-positive 
patients. 99/302 (33%) showed an “abnormal” 3QT (a3QT) and 82 (27%) had HAND. 
Sensitivity, specificity, positive and negative predictive value (PPV and NPV) were low 
and far from 80%, both in naïve and treated patients. HAND was not associated with 
a3QT, while an altered quality of life by SF-36 Health Survey was associated with a 
higher probability of a3QT in the multivariate model. 
- “NeuroHIV study”: 62/237 (26%) untreated and 44/116 (34%) cART-treated subjects 
presented HAND, with a prevalence of mild forms. In naïve patients low CD4+ nadir, not 
Italian origin and unemployment, while in treated subjects a longer length of HIV 
infection, non infectious comorbidities, symptoms of depression and detectable HIV-
RNA were independently associated with a higher probability of HAND. No association 
with longer time on cART, CPE score and type of cART regimen was observed. 50 
naïve and 10 treated patients repeated the same neuropsychological evaluation after 12 
months of virally suppressive cART and most of the them did not show any 
improvement of cognitive functioning. 
- “CSF/plasma HIV-RNA ratio study”: 50/155 (32%) untreated HIV-positive patients 
presented HAND. AIDS-defining diseases and a CSF to plasma HIV-RNA ratio ≥1 were 
associated with a 3-fold higher risk of HAND, adjusting for CD4+ nadir. 
- “Neuro MITO study”: 61/70 patients (87%) showed low CSF/Plasma RNA ratio (<1, L-
CSF) at baseline; L-CSF and H-CSF (high CSF/Plasma ratio, ≥1) patients showed 
comparable peripheral and CSF inflammation, T-cell activation/proliferation and 
maturation and HIV/CMV-specific response. After 12 months of cART both H-CSF and 
L-CSF patients showed a significant contraction of memory activated 
CD38+CD45R0+CD8+ T-cells, while maintaining stable neurocognitive performance. 
Interestingly, only L-CSF patients showed a reduction in CSF sCD14, IL-6 and MCP-1 
and in plasma TNF-α, an increase in naïve CD4+ and CD8+ and central memory CD4+ 
T cells, with a parallel reduction of terminally differentiated CD8+ T cells. With regard to 
cognitive performance, at baseline, 9/22 subjects presented altered neurocognitive 
evaluation: 5/16 (31%) L-CSF, 4/6 (67%) H-CSF, with no significant variation at T12. 
- “Case report of cognitive rehabilitation”: 3 treated patients with HAND underwent a 
computer-based rehabilitation program for 12 weeks. At the end (T1), the patients were 
tested again with the same neuropsychological battery. Patient 1 (current CD4+ count 
405/mmc, HIV-RNA <40 copies/ml) had a diagnosis of mild neurocognitive disorders 
(MND) at enrolment (T0) and a normal evaluation at T1. Patient 2 (CD4 T-cells 
366/mmc, HIV-RNA <40 copies/ml) had asymptomatic neurocognitive impairment (ANI) 
at T0 and a normal performance at T1. Patient 3 (CD4 T-cells 522/mmc, HIV-RNA <40 
copies/ml) had MND at T0 and normal cognitive functioning at T1. Patients’ adherence 
to the program was 100%.  
 
Conclusions 
 
Asymptomatic forms of HAND still have a relatively high prevalence, both in naïve and 
cART-treated patients. Given the low performance of 3QT in ascertaining cognitive 
impairment in HIV-infected patients, other quick screening tools for HAND are needed.  
The association of HAND with low CD4+ nadir and CSF/plasma HIV-RNA ratio ≥1 
supports the need of an early ART introduction, especially in foreigners and 
unemployed patients; the control of peripheral viral replication, the management of 
depression and non infectious comorbidities could probably prevent HAND in treated 
patients. Moreover, patients with high CSF/plasma HIV-RNA ratio showed a slower 
response in terms of peripheral and CSF pro-inflammatory/effector phenotypes under 
cART, supporting the need of a closer follow-up of these subjects, in order to rapidly 
reduce the viral burden and limiting the neuroinflammation and neurotoxicity. In a follow 
up period of 12 months of virological suppressive cART, the majority of HAND cases 
seemed to remain stable, suggesting that cognitive improvement requires a longer time 
or other approaches complementary to cART, such as cognitive rehabilitation. A 
computer-based restorative approach showed good results in term of improvement in 
neuropsychological performances in treated HIV-infected patients, thus requiring a 
validation in larger cohorts and with randomized controlled trials. 
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Definition and Prevalence of the HIV-Associated Neurocognitive Disorders 
(HAND) 
 
The HIV-Associated Neurocognitive Disorders (HAND) are a spectrum of cognitive 
deficits that could affect HIV-infected patients. Currently, there are four diagnostic 
criteria for the definition of HAND:  
(i) Frascati’s criteria or HAND criteria[1]  
(ii) the clinical rating (CR)[2] 
(iii) the global deficit score (GDS)[3]  
(iv) the multivariate normative comparison (MNC)[4].  
The HAND criteria, proposed by Antinori et al, recognize three different syndromes: 
Asymptomatic Neurocognitive Impairment (ANI), Mild Neurocognitive Disorders (MND) 
and HIV-Associated Dementia (HAD); these disorders are diagnosed with a 
standardized neuropsychological evaluation on the following cognitive abilities: 
verbal/language; attention/working memory; abstraction/executive; memory (learning; 
recall); speed of information processing; sensory-perceptual and motor skills. ANI is 
characterized by a cognitive impairment in at least two cognitive domains and of at least 
1.0 standard deviation (SD) below the mean for age and education appropriate norms; it 
does not interfere with day by day functioning. MND is defined by an impairment in 
cognitive functioning in at least two cognitive domains and of at least 1.0 SD below the 
mean for age and education with a mild interference in everyday life, such as a reduced 
mental acuity, inefficiency in work, homemaking or social activities. Finally, HAD is a 
severe cognitive deficit in at least two cognitive domains, but typically in multiple 
domains, and of at least 2.0 SD below the mean for age and education; HAD is also 
characterized by a striking impact on daily life. 
For the diagnosis of each of these disorders, other preexisting causes for cognitive 
impairment have to be excluded[1].  
According to CR, neurocognitive impairment is defined as a score of five to nine in at 
least two cognitive domains; demographically corrected test scores (T-scores) are 
categorized by cognitive domain and then CR scores for all domains are assigned on a 
scale ranging from 1 (above average) to nine (severely impaired) with a cut off of four 
for borderline cognitive disorders and of five for mild impairment[2].  
In GDS approach, T-scores are transformed in a deficit score that has a range from 
zero (no impairment) to five (severe impairment); the deficit scores are then averaged 
across all tests used for the neuropsychological evaluation to create the GDS[2]. The 
work of Carey et al in 2004 supported the validity of the GDS with a cut off of ≥0,5 to 
classify neurocognitive impairment in HIV-positive subjects[3]. 
Finally, MNC is based on one-sided Bonferroni corrected univariate as well as the one-
sided multivariate comparisons to correct the scores of the multiple tests that are 
administered for the complete neuropsychological evaluation[4].  
Recently, the POPPY Study investigated the level of agreement between Frascati’s 
criteria, GDS and MNC and tried also to correctly define cognitive impairment in HIV-
infected people. The authors found that especially Frascati and GDS showed a good 
agreement; however, the validity of these criteria is hardly assessable given the lack of 
a gold standard for HAND diagnosis. They then proposed that an optimal definition of 
HAND could capture patients with true pathological cognitive impairment and has to 
include subjects with the lowest cognitive performance scores and the greatest number 
of cognitive symptom complaints; these definition has still to be validated in the POPPY 
cohort, in other cohorts and in longitudinal studies[5, 6]. 
Due to the use of different diagnostic criteria, the reported prevalence of HAND changes 
from 15 to 55% of HIV-infected patients on antiretroviral treatment and from 30-35% of 
patients before treatment introduction, depending on the criteria used[5, 7-10]. 
Approximately 20% of patients died for HAD before the introduction of combination 
Antiretroviral Therapy (cART) and most of the subjects who died for HAD presented 
encephalitis at autopsy. Nowadays HAD is observed only in a smaller proportion of 
patients (1-4%), while less severe, but potentially disabling forms are the prevalent ones 
and these manifestations occur earlier during the course of HIV infection [8, 11-13]. In the 
Central Nervous System (CNS) Anti-Retroviral Therapy Effects Research (CHARTER) 
Cohort, one of the most largest cohort studying neurocognitive impairment in HIV-
positive subjects, HAND was diagnosed in 47% of patients and specifically ANI in 33%, 
MND in 12% and HAD in 2%[14].  
Risk factors and confounders  
 
Well-known risk factors for HAND are low CD4+ T cell count, high plasma and 
cerebrospinal fluid (CSF) HIV-RNA before antiretroviral therapy and AIDS-defining 
diseases[15, 16]. After the introduction of cART, significant changes in the clinical features 
of HAND have been reported. 
In fact, severe immune depression, high viral replication, HIV-related medical symptoms 
(such as anemia, low weight and fatigue) and the presence of extrapyramidal signs on 
neurological examination were associated with an increased risk of HAD before cART, 
while many of these factors are no longer associated with less severe forms of HAND in 
cART-treated subjects[9]. Nowadays risk factors for mild forms of neurocognitive 
disorders are advanced age, low CD4+ nadir and cardiovascular risk factors [7, 17-21]. 
Patients with AIDS diagnosis and CD4+ count <200 cells/mmc still have a higher risk of 
developing HAND before the age of 50 years. The association between viral load and 
MND or ANI however is less clear than before, as suggested by the appearance of 
HAND also in treated patients with undetectable plasma and CSF HIV-RNA[7, 22, 23]. 
Several comorbidities have to be considered in the diagnosis of HAND, such as 
psychiatric conditions like severe depression and anxiety, age-related cognitive deficits, 
HCV coinfection, alcohol and substance abuse, nutritional and vitamin deficiencies, 
traumatic brain injury, accelerated atherosclerosis, obstructive sleep apnea and sleep 
disorders[7]. Given the ageing of HIV-infected population, cerebrovascular disease risk 
factors, as well as hypertension, diabetes and hypercholesterolemia, play a major role 
in contributing to cognitive deficits[13, 24]. Currently, the highest prevalence of these 
disorders is in the age group over 50 years; thus, the differential diagnosis of HAND 
must consider all comorbidities, expecially age-related ones[7, 13, 25, 26]. 
 
Clinical oucotme and temporal progression  
 
Mild forms of HAND can have significant functional impairment in activities of daily living 
and have impact not only on the quality of life, but also on the survival [27]. The mean 
survival for patients diagnosed with HAND has considerably improved recently: in 1993-
1995 survival for HAD was only 5 months, while in 1996-2000 increased to 38.5 months 
and patients with HAND on current cART regimens have a quite normal life span[9]. 
However, according to a population-based study of 1602 HIV-positive patients mortality 
risk is three-fold higher in subjects with HAND compared to individuals without 
neurocognitive impairment[27]. Furthermore, also patients with asymptomatic forms 
(ANI), even with suppressed plasma viral load, displayed a two to six higher risk of 
developing symptomatic HAND during several years of follow up, in comparison to 
subjects without neurocognitive disorders, according to the CHARTER study[28]. Finally, 
neurocognitive disorders could reduce treatment adherence and could also worsen side 
effects of therapies with subsequent altered quality of life[27, 29].  
The temporal modification of HAND also changed in the cART era. Before cART 
introduction, HAD was rapidly progressive; in HIV-positive patients on virological 
effective treatment most individuals with HAND generally seem remain stable with a 
small proportion of patients showing deterioration, but rarely they improve or 
recovered[13]. In a 4-year recent study no modifications of HAND were reported in 77% 
of patients, while 13% progressed to a more severe form and 10% improved[7]. Similar 
results were described in a longitudinal study over 5 years[30]. 
Pathogenetic aspects  
 
Entry of HIV in the CNS 
HIV can infect brain very early in the course of infection and can persist in the CNS for 
years; neuroimaging techniques have demonstrated brain changes already in the first 
100 days after infection and the virus has been found in CSF and in brain biopsies even 
in the first weeks after HIV transmission[31]. In a cross-sectional study on 96 HIV-
infected patients with primary HIV infection (PHI) and median 77 days post infection, 
CNS infection and immune activation was similar to the levels found in the chronic 
phase[31]. The early neuro-invasion could also explain the neurological disorders that 
some patients manifest in the acute phase of infection (meningitis, encephalitis, 
myelopathy and polyneuropathy).  
Neuropathogenesis of HAND is a complex mechanism that begins with the invasion of 
the CNS by the virus and a productive infection of perivascular macrophages and 
microglia[32].  
It is thus well recognized that HIV can cross the blood brain barrier (BBB) and invade 
the CNS; three different mechanisms have been proposed for the entry of the virus in 
the CNS[7, 33-35] (Figure 1): 
(i) HIV can directly infect endothelial cells and they could release viral particles 
in the CNS; in fact, endothelial cells could express chemokine receptors 
involved in the HIV entry, like CXCR4, CCR3, DC-SIGN and L-SIGN. 
(ii) The virus may cross directly the BBB, especially if the BBB is damaged or 
has an increased permeability; some pro-inflammatory cytokines, such as 
TNF-α secreted by infected macrophages, could increase BBB 
permeability[36, 37]. HIV could alter the permeability of BBB damaging the 
stability of tight junctions proteins[38, 39]. Cell-free virus particles can penetrate 
brain microvascular endothelial cells (BMVECs) thanks to an up-regulation of 
the expression of the intercellular adhesion molecule ICAM-1. 
(iii) HIV infected monocytes, leukocytes and perivascular macrophages can pass 
the BBB and release viral particles in the CNS[40]. Viral particles are then able 
to infect resident cells such as microglia, establishing a persistent infection 
(“Trojan horse” hypothesis)[41]. The most important actors of this process are 
CD14lowCD16high monocytes, that are an intermediate subset between 
monocytes, differentiated macrophages and dendritic cells, and seem to be 
more permissive to HIV replication and more easily cross the BBB[42]. 
Neuro-inflammation and neurotoxicity 
After the invasion of the CNS by the virus, a process of neuro-inflammation starts. 
Infected monocytes and lymphocytes can produce other viral particles; cellular factors 
and resident CNS cells are infected by viral particles infiltrating the CNS or released 
from infected cells. Monocytes and T cells infected with HIV can then release pro-
inflammatory cytokines, such as TNF-α and IL-1B, which in turn activate microglia. The 
activation of these cells leads to recall from the peripheral blood of other cytokines, 
chemokines, products of microbial translocation and infected cells. Activated microglia 
can also produce neurotoxic factors, such as inflammatory mediators, platelet-derived 
growth factor (PDGF), nitrogen oxide and quinolinic acid (QUIN) with subsequent 
activation of astrocytes[43, 44]. Astrocytes can not release virions under normal 
conditions, but it has been demonstrated that they can release non-structural proteins of 
HIV and promote inflammation[45]. Both viral and host factors are able to damage brain 
glutamate metabolism and neurotransmission; in patients with HAND increased CSF 
levels of glutamate have been reported, in comparison to subjects without 
neurocognitive disorders. Viral proteins, like Tat and gp120, are able to decrease glial 
and synaptic glutamate uptake, increase glutamate release from nerve endings and 
phosphorylate glutamate receptors leading to an increased toxicity of this 
neurotransmitter[46-48]. The final increased excitotoxicity causes dysfunction and 
neuronal death[7, 33, 49]. Finally, the release of different viral proteins in the CNS could 
amplify the BBB permeability with increase of neuroinvasion form the periphery [37] 
(Figure 2). A kind of vicious circle is thus established and could persist also when the 
initial stimulus, the viral replication, is suppressed by cART[7]. 
 
Role of CSF and peripheral viral load and immune activation  
As regard the correlation between CSF viral load and impaired cognitive function, in 
antiretroviral-naïve patients high levels of HIV-RNA on cerebrospinal fluid (CSF) have 
been described in HAD, correlate with the severity of dementia and predict future 
worsening of cognitive functions[50]. However, still nowadays the correlation between 
CSF HIV-RNA levels and mild forms of HAND is controversial[23, 51-53]; in fact, 
neurocognitive impairment could also occur with low CSF viral load and very 
occasionally with CSF HIV-RNA below the detection limit [54-56]. Previous studies on 
cohorts of untreated HIV-infected patients have reported median CSF viral burden 
between 1000 and 10.000 copies/mL, about 1 log lower than plasma viremia[31]. 
Systemic HIV replication plays also a role in the pathogenesis of cognitive impairment: 
HIV-RNA levels in plasma are independently associated with neurocognitive disorders 
and strongly correlate with CSF viral load[11, 12].  
In addition to HIV-RNA, chronic intrathecal inflammation and immune activation have 
been demonstrated in patients with HAND[22, 57-60]; previous studies have shown that in 
the earliest period of infection median CSF to plasma HIV-RNA ratio is lower than 
during chronic infection and could indicate a clear distinction between plasma and CNS 
compartment, but the extent of normal BBB’s disruption and intrathecal inflammation is 
similar, suggesting an early initiation of CNS immune activation with a subsequent 
possible neuronal dysfunction[31]. A further confirmation of this process could be that 
most individuals also during primary HIV infection, despite lower viral load in CSF 
compared to plasma, display high CSF concentrations of neopterin, an indicator of 
macrophage activation, CXCL10, a chemokine associated with CSF lymphocytosis, and 
neurofilament protein light chain (NFL), a marker of axonal injury[31]. During long term 
antiretroviral therapy, it is well demonstrated that levels of immune activation in blood 
and CSF are reduced[61], although elevated levels of these biomarkers and activated T 
cells could persist in CSF[43, 62-64]. The percentages of activated CD4+ and CD8+ T-cells 
increase in CSF, since the earliest phases of HIV infection[65]; in particular, detection of 
CSF IFN-gamma expressing CD8+ T cells, absence of cytolitic CD8+ cells and low 
CD4+ T cells responses to HIV are correlated with the severity of neurocognitive 
impairment[66]. 
The possible relationship between cognitive function and peripheral inflammation in 
HIV-infected patients has also been investigated[67]: in fact, non invasive and cost-
effective plasma biomarkers of neurocognitive impairment would be more useful and 
easy to perform than current methods of invasive CSF analysis and neuroimaging. 
Severe immune depression plays a main role in the development of neurocognitive 
disorders: a clear association between low CD4+ lymphocyte count at nadir and 
cognitive impairment has been well demonstrated and, in the pre-cART era, HAD 
almost exclusively occurred in patients with current CD4+ T cell counts below 200 
cells/mmc[66]. Conversely, during viro-immunological efficient cART even subjects with 
normal or near-normal CD4+ T cells could develop neurological disorders[68]. More 
recently, the correlation between CD4/CD8 ratio’s inversion and cognitive impairment 
has been investigated, considering that the inversion of CD4/CD8 ratio can be used as 
a marker of immune activation and age-associate disease: interestingly, HAND resulted 
independently associated with a CD4/CD8 ratio <1 in the group of virologically 
suppressed patients with MND, while this association was not confirmed in subjects with 
ANI[69-71]. Lower peripheral CD8+ counts at presentation and a higher proportion of 
CD4/CD8 ratio inversion were observed in impaired patients also in other studies[72]. 
A higher degree of neurocognitive deficits on cART has been associated not only with 
the inversion of CD4/CD8 ratio, but also with a higher immune activation of CD4+ and 
CD8+ cells and with a shift from naïve to effector memory T cells[73]. Thus, the low 
CD4/CD8 ratio with a skewed T cell differentiation could identify patients at a potential 
risk of developing neurocognitive impairment, despite immune-virological response to 
cART[71]. 
So far, however, the correlation between peripheral T-cells homeostasis, CSF HIV-RNA 
and neurocognitive deficits, especially in untreated patients, is not well known and 
deserves further studies.  
 
Screening and diagnosis  
 
Screening tests 
The European AIDS Clinical Society (EACS guidelines, version 9, October 2017) states 
that neurocognitive impairment has to include (Figure 3): 
(i) marked acquired impairment in cognitive functioning involving at least 2 cognitive 
domains, as documented by a performance of at least 1 SD below the mean for age-
education appropriate norms on neuropsychological tests; 
(ii) interference in daily functioning; 
(iii) no evidence of another pre-existing cause for the dementia. 
After the exclusion of obvious confounding conditions (severe psychiatric diseases, 
abuse of alcohol and psychotropic drugs and previous or current CNS opportunistic 
infections or other neurological diseases), cognitive deficits have to be screened in 
symptomatic HIV-infected patients at diagnosis and before cART introduction. The 
screening has to be done by the following 3 questions that may be used to guide 
physician assessment: 
1. Do you experience frequent memory loss (e.g. do you forget the occurrence of 
special events even the more recent ones, appointments, etc.)? 
2. Do you feel that you are slower when reasoning, planning activities, or solving 
problems? 
3. Do you have difficulties paying attention (e.g. to a conversation, book or movie)? 
For each question the answer could be. a) never, b) hardly ever, or c) yes, definitely. 
HIV-infected patients who answer “yes, definitely” on at least one question are 
considered to have an “abnormal” result and have to be evaluated for depression. If the 
diagnosis of depression is excluded or the disease is optimally treated, but the cognitive 
problem persists, the patients have to undergo a complete neuropsychological 
examination[74]. A comprehensive neuropsychological evaluation is the gold standard for 
the assessment of HAND. The administration of a complete neuropsychological testing 
is however time-consuming and requires trained staff, limiting its use in clinical settings 
and for screening purposes. There is therefore need for brief and easily accessible tools 
for the HAND screening. So far different screening tests have been proposed, but there 
is not consensus on the most adequate one[75-77].  
Among screening tests, the Montreal Cognitive Assessment (MOCA) is frequently used, 
but it is not designed specifically for HIV-infected patients and is not culturally 
appropriate for global use[78-84]. International HIV Dementia Scale (IHDS) is another 
widely used tool, but has some limitations at the cut off score of ≤10 in discriminating 
between mild and more severe forms of HAND[75, 81, 85-87].  
Several studies have therefore demonstrated that the combination of different screening 
tests or brief computerized screening batteries, including different combinations of 
standardized neuropsychological tests, could improve sensitivity and specificity and 
suggest this approach for the screening of HAND[81, 88-91].  
 
Neuropsychological evaluation 
The comprehensive neuropsychological examination has to include tests exploring the 
following cognitive domains: fluency, executive functions, speed of information 
processing, attention/working memory, verbal and visual learning, verbal and visual 
memory and motor skills. The examination is then completed by the assessment of daily 
functioning through the Instrumental Activities of Daily Living (IADL)[74] (Figure 4).  
All tests are administered by trained neuropsychologists and scored in accordance with 
published manuals. Raw scores were converted to demographically adjusted normative 
T scores; all scores are also adjusted for age and length of education[1, 91] (Figure 4). 
 
Neuroimaging 
To diagnose and manage HIV-associated neurocognitive impairment, a neurological 
examination, brain MRI and CSF examination have to be performed also to exclude 
other diseases. The quantification of HIV-RNA on CSF and, where appropriate, 
genotypic drug resistance (GDR) in paired CSF and plasma samples have to be 
assessed[74]. Different neuroimaging techniques have been studied for the diagnosis 
and the monitoring of HAND[92]; beside standard MRI, magnetic resonance 
spectroscopy (MRS), volumetrics and diffusion tensor imaging (DTI), functional MRI 
(fMRI) and positron emission tomography (PET) have been used in HIV-infected 
patients in research settings. Most common radiological findings of HAND are brain 
atrophy, demyelinization and white matter alterations[93-97]. 
 
Lumbar puncture 
Lumbar puncture for the determination of CSF viral load allows the identification of CSF 
viral escape, that is defined as CSF HIV-RNA ≥1 log10 copies/mL compared to plasma 
HIV-RNA or the presence of detectable CSF viral load when plasma viremia is 
undetectable[98]. Viral escape can occur in 4-21% of cART treated patients and is 
associated with CNS immune-activation[99, 100]. The mechanisms leading viral escape in 
CSF and its risk factors are not completely understood. Potential risk factors for viral 
escape could be inadequate CNS penetration by some cART regimens, persistent low-
level viremia (LLV), length of time on cART, drug-resistance mutations in CSF and low 
CD4+ nadir[101]. Given the not exact correlation between CSF HIV-RNA levels and 
neurological symptoms, also the clinical features of patients with CSF viral escape do 
not seem so clear[70, 102, 103]. However, besides some cases of asymptomatic patients 
harbouring up to 200 copies/mL of CSF HIV-RNA, several case series describe subjects 
with new neurological symptoms, CSF viral escape and clinical improvement after 
switching cART regimens[55, 104-107]. 
 
 
 
Biomarkers 
In research settings a lot of biomarkers have been identified, even if no one could be 
used in routine clinical practice[108]. Saylor D and colleagues proposed a classification 
for the available biomarkers in four groups: immune activation, metabolic or cellular 
stress, neuronal injury and neuroimaging markers[7]. Another possible classification 
includes monocyte activation markers, cerebral injury markers, inflammatory cytokines 
and proteins, chemokines and cardiovascular markers (Figure 5). The most widely 
studied biomarkers are the following: 
 
Neopterin: CSF and plasma neopterin has been used as a soluble marker of CNS 
inflammation, as it is produced by activated macrophages and astrocytes, mainly in 
response to interferon-gamma[109]. It has been shown that 97.5% of neopterin in CSF is 
intrathecally produced, and it is not simply a passage from blood. Levels of CSF 
neopterin correlate with neurofilament light chain, a marker of neuronal injury [110].  
 
Neurofilaments (NFLs) are structural proteins that are specific for neurons and are 
released into the CSF and blood following axonal disruption or degeneration [111]. In HIV 
infection, CSF NFLs levels are elevated since the earliest phases of infection[63], also in 
patients with mild forms of HAND[112]. Moreover, plasma and CSF NFLs levels are 
highly correlated, thus the plasma NFLs levels can be useful to assess the presence of 
active CNS injury[113]. 
 
LPS and sCD14. During HIV infection, the gastrointestinal mucosa undergoes a 
massive T cells depletion, leading to translocation of microbial products such as 
lipopolysaccharide (LPS) into the systemic circulation[114]. LPS is able to activate innate 
immune system cells thanks to Toll-like receptor-4 (TLR-4) and its binding with CD14. 
CD14 is expressed on monocytes, macrophages, and neutrophils, and upon stimulation 
by LPS, as well as other microbial products, CD14 is secreted and cleaved from the 
cells as soluble form (sCD14)[115] . Plasma sCD14 levels independently predict mortality 
and impaired neurocognitive test performance in HIV-infected subjects[116]. Thus, 
sCD14 is an excellent candidate biomarker of monocyte/macrophage activation 
associated with HIV-induced neurodegeneration. A recent study demonstrated, in 
untreated patients, a positive correlation between expression of CSF NFLs isoforms and 
CSF sCD14, thus directly linking CNS monocyte/macrophage activation with neuronal 
injury[64]. 
 
CD163, a monocyte-associated hemoglobin/haptoglobin complex scavenger receptor, is 
cleaved and shed from activated monocyte/macrophages in a soluble form (sCD163) in 
inflammatory states. Plasma sCD163 levels are elevated in HIV-infected subjects, 
particularly those with cognitive impairment[117]. In addition, CD163+ 
monocytes/macrophages accumulate in perivascular brain regions in individuals with 
HIV encephalitis[118]. The number of perivascular CD163+ monocyte/macrophages 
positively correlates with plasma HIV load, suggesting trafficking of peripherally 
activated monocytes to perivascular areas in the brain[118]. Finally, increased plasma 
sCD163 levels have been demonstrated in cognitively impaired HIV-infected individuals 
compared with non-impaired individuals and plasma sCD163 highly correlates with CSF 
sCD163 levels[117, 119].  
 
TNFα. Tumor necrosis factor-α is a pro-inflammatory cytokine produced by 
macrophages, circulating monocytes and microglia. Although there is evidence that 
TNFα may protect neuronal cells by promoting astrocytosis, activating NF-kB, 
stimulating antioxidant pathways and limiting the inflammatory response, TNFα also 
damages CNS cells through direct and indirect mechanisms. These pathogenic effects 
include oligodendroglial toxicity and demyelination, resident microglial activation and 
disruption of the BBB[120]. This cytokine is significantly increased in the HIV infected 
brain and has been shown to correlate with the HAD severity and the degree of immune 
activation[121]. 
 
IP-10 (CXCL10). Interferon- -inducible protein 10 is expressed by astrocytes, microglia 
and endothelial cells during inflammation and acts specifically on activated T cells and 
macrophages, attracting T lymphocytes into the CSF[122]. In the brain, IP-10 can be 
induced by HIV-1 viral gp120, Nef, and Tat. Cooperative interaction of HIV Tat and IFN-
  results in IP-10 over-expression, which in turn can amplify the inflammatory responses 
within the CNS by recruiting more lymphocytes into the brain[123]. IP-10 has been 
detected in the CSF of individuals with HIV-1 infection and in the astrocytes of 
individuals with HAD[124]. Yuan L. et al demonstrated that the expression of IP-10 was 
significantly elevated in HIV-infected patients with neurocognitive impairment whether in 
CSF or in plasma[122].  
 
IL-6 is an activator of acute phase responses and is involved in crosstalk with other 
inflammatory mediators. IL-6-mediated inflammation is known to cause a higher 
incidence of gliosis and dendritic damage in patients with Parkinson’s disease, 
amyotrophic lateral sclerosis, multiple sclerosis and Alzheimer Disease[125]. High plasma 
levels of IL-6 are associated with worse cognitive function in HIV-infected patients, 
supporting a role for chronic inflammation in neurocognitive decline[126, 127]. 
 
MCP-1. The monocyte chemoattractant protein-1 is a chemokine that is expressed 
during inflammation and that, upon activation of its receptor (CCR2), can induce 
chemotaxis of monocytes to inflammatory sites. MCP-1 is expressed by monocytes, 
macrophages, dendritic cells, neurons, astrocytes, microglia and endothelial cells[128, 
129]. 
MCP-1 levels in the brain and cerebrospinal fluid (CSF) are elevated in HIV-infected 
patients with encephalitis, AIDS dementia and HIV-positive patients with cerebral 
inflammation[130]. 
 
s100β is a calcium binding protein that is expressed almost exclusively by astrocytes in 
the brain and is a marker of astrocytosis[131]. The presence of s100β in peripheral blood 
is an useful indirect marker of BBB damage and its levels have been associated with 
cognitive impairment in HIV-infected patients[132]. 
 
HIV proviral DNA. In cART-treated patients the circulating peripheral HIV proviral DNA 
load in macrophage/monocytes (CD14/CD16) is associated with HAD and minor 
cognitive motor disorders, independently of HIV RNA levels[133]. The total amount of 
circulating HIV-DNA associates with an increased risk of HAND also in treatment-naïve 
subjects with advanced immune suppression[134]. This marker also correlates to MRS 
markers of brain injury and to neopterin levels[135]. 
 
Any single biomarkers is however insufficient to identify early stages and minor forms of 
HAND; thus, to date a validated biomarker for the diagnosis and the follow up of HAND 
has still to be found. 
Clinical features 
 
HAND is characterized by an insidious onset with a slow progression. Neurocognitive 
disorders are associated with several dysfunctions: decrease of attention, mood 
alterations, depression, psychomotor disturbs, alteration in the extrapyramidal 
movements and spasticity[33]. In the earliest stages difficulties in concentration and 
memory and impaired executive functions predominate, while psychomotor slowing, 
depression, irritability and subclinical motor signs are the most frequent characteristics 
with the progression of the disease. If untreated, a progression towards dementia with 
mutism and incontinence could be observed[13]. 
Clinical features of HAND have also changed in the cART era; extrapyramidal signs like 
bradykinesia, rigidity, tremor and motor signs are now less common. Regarding the 
neuropsychological profile, before cART cognitive impairment involved more commonly 
subcortical area with psychomotor slowing, motor dysfunction and memory deficit, while 
nowadays a mixed pattern of both cortical and subcortical features prevails with higher 
impairment in executive functions and working memory[14]. 
 
Therapeutic approaches 
 
cART is the only therapeutic possibility in HIV-infected patients with HAND, but unluckily 
it is effective only in a subset of patients. Early initiation of cART seems to be essential 
to prevent the establishment of neurocognitive disorders, that are then very difficult to 
treat. However, in the START trial early cART initiation does not have a great impact on 
HAND; although early cART introduction results in fewer AIDS-related diseases in 
comparison to patients with deferred therapy, neurocognitive performance does not 
differ between groups after a mean of 3.3 years of follow up[136]. 
A recent study has not confirmed these results: according to Robertson et al, the cART 
start very shortly after HIV acquisition results in greater improvement in neurocognitive 
performance of HIV-infected patients compared to defer treatment after 24 weeks[9].  
However, as possible explanations of these contrasting results we have to consider that 
in the START trial the mean follow up of patients was not so long, there was a high 
proportion of subjects on potentially neurotoxic efavirenz and low rates of HAND were 
found due to short disease duration and high CD4+ counts[137].  
The CNS penetration effectiveness (CPE) score was developed by Letendre et al in 
order to rank drug penetration and efficacy in the CNS[138]; the initial and updated 
ranking systems have then been validated in the CHARTER cohort[139] (Figure 6). In this 
ranking system, cART drugs are hierarchically assigned a value from 1 (low) to 4 (high) 
according to published data about: 
(i) effectiveness in the CNS (pharmacodynamics),  
(ii) drug concentrations in CSF (pharmacokinetics), 
(iii) drug characteristics (i.e. protein binding).  
The values for all drugs in a regimen are then summed up to yield a final CPE score. 
Higher CPE scores correlate with undetectable CSF viral loads, suggesting that this 
score may provide useful information to select cART regimens that better control HIV 
replication in the CNS and reduce HIV-related brain injury. A review on this topic found 
that the majority of published studies reported an association between regimens with 
higher CPE and either decreased CSF viral load or better neurocognitive outcomes [140]. 
However, the correlation between CPE score and neurocognitive performance is still 
controversial, given that other studies did not find any association or reported even a 
worse cognitive outcome associated with higher CPE scores[141-143] and thus the utility 
of the CPE score remains controversial. These contrasting results may be attributed to 
the study design and statistical power differences, the failure to adequately account for 
confounders and the neurotoxicity of some cART drugs. Indeed, the CPE score is 
limited by its categorical scoring, unclear weighting of each criterion (pharmacokinetic, 
chemical properties, etc.), and lack of consideration of toxic effects or drug interactions. 
Furthermore, the CPE score relies on CSF drug concentrations, which may not reflect 
the brain parenchymal pharmacokinetics, and efficacy in glial cells is not considered, 
primarily due to limited available data[76]. The efficacy of CNS-penetrating antiretrovirals 
in astrocytes and macrophage-lineage cells have been studied using in vitro models of 
infection: all the studied agents could inhibit HIV infection in macrophages with 
concentrations typically found in CSF and similar results were found in astrocytes, 
except for lamivudine, stavudine, and zidovudine, which required greater 
concentrations, suggesting that these drugs probably do not adequately treat astrocyte 
reservoirs[144]. 
Recent studies suggest that CCR5 receptor interactions with CNS reservoir cells are 
associated with HAND. Maraviroc, a CCR5 receptor antagonist, has adequate CSF 
penetration, inhibits CNS viral replication, including in monocyte/macrophage cells, and 
has anti-inflammatory properties in the CNS. A recent prospective, open-label, pilot 
randomized controlled trial in individuals with viral suppression and stable cART for 12 
months found maraviroc-intensified cART improve global neurocognitive performance at 
both 6 and 12 months without significant side effects[145]. Current randomized controlled 
trials are investigating the effects of cART intensification with maraviroc or dolutegravir 
on neurocognitive performance. 
Given the potentially confounding CNS effects of efavirenz (EFV) and the detrimental 
effects on neurocognitive function of EFV[146] and nucleoside sparing regimens, such as 
protease inhibitor monotherapy[147], current international guidelines recommend to avoid 
these regimens as first-line treatment in patients with HAND. Considering the 
uncertainty in literature about better neurocognitive performance with CNS-penetrating 
antiretrovirals, guidelines do not recommend to take in consideration CPE score in 
therapeutic decision for starting cART in HIV-infected patients with HAND; however, at 
least in subjects with symptomatic CNS disease, probably also CPE score has to be 
considered[13, 76] and EACS guidelines suggest to consider the inclusion of potentially 
CNS-active drugs. A CNS-active drug is characterized by: 
(i) a demonstrated CSF penetration when studied in healthy HIV-positive 
populations (concentration above the IC90 in >90% examined persons) 
(ii) proven efficacy on cognitive function or CSF HIV-RNA decay in a short-term 
period (3-6 months) when evaluated as single agents or in peer-reviewed 
controlled studies. 
In patients already on cART the management of HAND is still more complicated. 
Generally, cART should optimized according to plasma and CSF GDR test[76]. In 
patients without CSF viral escape, the decision of switching cART or continuing the 
same regimen depends on each specific situation and other causes for neurocognitive 
impairment have to be searched[74] (Figure 3-Figure 7). 
As a result, there is no definitive HAART guideline for HAND and further investigations 
with randomized controlled trials are needed[13, 77, 92, 144]. 
The absence of an optimal first-line pharmacotherapy for HAND has led researchers to 
explore cognitive and behavioral approaches. In the last years some pilot studies 
investigating computerized rehabilitation on HIV-infected patients have been 
conducted[148-151]. Even if their outcome was not the resolution of HAND, but the 
improvement of specific neurocognitive functions, such as learning memory and speed 
of processing, their initial results are encouraging, providing important information 
regarding a possible strategy for the future treatment of cognitive deficits[150, 152, 153]. 
Moreover, in 2015 Livelli et al. have shown data about the efficacy and stability over 
time of a cognitive rehabilitation protocol in treated HIV+ patients with HAND[154]. 
Indeed, non-antiretroviral treatments (intranasal insulin, IL-1 antagonists, paroxetine 
and complement inhibitors, as well as limiting the replication of viral transcripts by Tat 
monoclonal antibodies, antisense oligonucleotides and adjunctive neuroprotective 
strategies) have been tested for the treatment of HAND without a clear clinical 
benefit[13]. Non pharmacological interventions that may have a positive clinical effect are 
the correct management of concurrent subclinical and clinical diseases, such as HCV 
infection, major depressive disorders, cardiovascular and metabolic comorbidities; 
another crucial step has to be the improvement of cART adherence[76]. A 
comprehensive algorithm for the management of HIV-positive patients with HAND has 
been proposed by Calcagno A et al and includes the prevention and treatment of age, 
virus and drug-associated comorbidities[144] (Figure 8). 
 
 
 
 
 
 
 
  
 
 
Aim 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mild forms of neurocognitive impairment are still quite common among HIV-infected 
patients, especially in cART treated patients, also in the context of suppressed viral 
replication in periphery. Besides traditional risk factors, ageing and vascular 
comorbidities are acquiring more and more evidence as cofactors in the pathogenesis 
of cognitive impairment in HIV-infected patients. Despite the gold standard for the 
diagnosis of HAND is a comprehensive neuropsychological evaluation, it is not always 
applicable in the clinical routine and thus the search for the perfect screening test is still 
ongoing. Finally, no effective treatment for HAND is currently available. 
In this context, the aim of this study was: 
-to explore the performance of the “Three Questions Test”, proposed by the European 
AIDS Clinical Society (EACS guidelines, version 9, October 2017), for the screening of 
cognitive impairment in HIV-infected patients; 
-to investigate the prevalence, the clinical and viro-immunological correlates of the HIV-
associated neurocognitive disorders in a cohort of antiretroviral-naïve and cART treated 
HIV-positive patients; 
-to observe the modification of HAND after at least 12 months of virological effective 
antiretroviral treatment; 
-to explore a panel of peripheral and CNS inflammatory and immune activation markers 
in untreated HIV-infected patients and the effects of 12 months of virally-suppressive 
cART, according to CSF/plasma HIV-RNA ratio; 
-to investigate the efficacy of a new computer-based program complementary to cART 
in improving cognitive functioning. 
We thus performed the following studies: 
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performance of 3QT 
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Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The San Paolo Infectious Diseases (SPID) Cohort 
 
The study was conducted at the San Paolo Infectious Diseases Cohort (SPID cohort). 
The SPID Cohort has been established in 2006 with the objective to conduct clinical 
research’s studies about HIV infection, hepatitis coinfection and sexually transmitted 
diseases; adult HIV-positive patients that are in active follow up at the Clinic of 
Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of 
Health Sciences, University of Milan, Italy, are enrolled in the cohort after signing an 
informed consent. The data are collected during the routine blood exams and follow up 
visits; the database is reviewed once a year to correct eventual mistakes and missing 
data. 1143 patients are currently enrolled: 826 (76.6%) are males and median age is 
48.4 (IQR 47.8-49) years. 1118 (98%) are on antiretroviral treatment.  
 
Neuropsychological battery  
HIV-infected patients enrolled in the study underwent a comprehensive 
neuropsychological evaluation. This evaluation was performed at our Centre by a 
trained neuropsychologist; routinely, in our centre this evaluation is proposed to all HIV-
infected patients at the first diagnosis of infection before the introduction of antiretroviral 
treatment. cART-treated patients underwent the same neuropsychological assessment 
if they report cognitive symptoms during routine follow up visits. The neurocognitive 
battery includes 11 tests exploring 7 main cognitive domains (Table 4): speed of 
information processing [Trail Making Test Part A, Symbol Digit Modality Test, Stroop 
Color Test–Time]; learning and memory [Rey Auditory Verbal Learning Test Immediate 
Recall and Delayed Recall, Rey Osterrieth complex Delayed Recall]; 
abstraction/executive functioning [Stroop Color Test–Error, Trail Making Test Part B 
(TMT-B), Rey Osterrieth complex Figure Copy]; verbal fluency [Semantic and Phonemic 
Fluency]; attention/working memory [Corsi’s block Tapping Test, Forward and Backward 
Digit span, Trail Making Test Part BA]; motor skills [Finger Tapping Test]; the 
neuropsychologist also performed a functional assessment through the Instrumental 
Activities Of Daily Living (IADL). Raw scores on each test were calculated. Scores were 
corrected for age, educational level and gender using Italian normative data. In 
particular, the raw scores were first adjusted and then transformed into new 
standardized scores (named Equivalent Scores) on an ordinal scale ranging from 0 
(pathological performance) to 4 (best performance)[155]. Frascati’s criteria were used for 
the diagnosis of HAND[1]. 
The neuropsychological assessment includes also evaluation for Anxiety and 
Depression symptoms with the Hospital Anxiety and Depression Scale (HADS) and 
evaluation for Quality of Life with the SF-36 Health Survey (SF-36).  
 
Instrumental Activities Of Daily Living 
Instrumental Activities Of Daily Living (IADL) is an eight-item questionnaire that includes 
functional evaluations about the ability of use the telephone, engage in cooking, 
shopping, housekeeping and laundry, use of transportation, medication and financial 
management[156, 157]. For each question there are three possible answers and the 
scoring for each response is: three points for independent, 2 points for any assistance 
needed, 1 point for totally dependent. The presence of any assistance in daily living is 
considered a positive score. 
 
Hospital Anxiety and Depression Scale (HADS) 
To assess psychological distress in non-psychiatric patients, the Hospital Anxiety and 
Depression Scale (HADS) is a frequently used self-rating scale to measure symptoms 
of anxiety and depression. It consists of two subscales, Anxiety and Depression, and 
includes 14 items, seven items for the anxiety subscale (HADS Anxiety) and seven for 
the depression subscale (HADS Depression). HADS Anxiety focus mainly on symptoms 
of generalized anxiety disorder and HADS Depression is focused on anhedonia, the 
main symptom of depression. Each item is scored on a response-scale ranging 
between 0 and 3. After adjusting for six items that are reversed scored, all responses 
are summed to obtain the two subscales. Recommended cut-off scores according to 
Zigmond AS are 8–10 for borderline cases and ≥11 for definite cases[158, 159].  
The symptoms of depression could be also investigated through the Beck Depression 
Inventory-II (BDI-II) The BDI-II has a high validity and reliability in measuring depressive 
symptoms. It includes 21 symptoms from 0 to 3 according to how the patient felt during 
the past 2 weeks. The cut-off scores are: 0−13, minimal depression; 14−19, mild 
depression; 20−29, moderate depression; and 29−63, major depression. All patients 
with a BDI-II score of ≥ 20 have to be addressed to a psychiatric evaluation[160].  
 
SF-36 Health Survey (SF-36) 
SF-36 Health Survey is one of the most used instrument to assess quality of life. It is a 
questionnaire based on eight multi-item health domains (35 items): physical functioning 
(10 items), bodily pain (2 items), limitations due to physical health problems and 
personal or emotional problems (7 items), bodily pain (2 items), emotional well-being (5 
items), social functioning (2 items), fatigue (4 items) and general health perceptions (5 
items). These eight scales are then aggregated into two summary measures: Mental 
Health Index (MHI) and Physical Health Index (PHI). The 36th item, that provides an 
indication of perceived change in health, is not included in the summary scores. The 
responses are scored in a two-step process: first, precoded numeric values are recoded 
per the scoring validated key and each item is scored on a 0 to 100 range; then, in step 
2, items in the same scale are averaged together to create the 8 scale scores. Higher 
scores define a more favorable health state. There is not a standardized cut off, but a 
database of normative data is available to calculate the norm-based score that identifies 
the pathological cases.[161-164].  
 
 
According to the study in which patients were enrolled, after signing an informed 
consent, HIV-infected individuals could also undergo blood exams to detect plasma 
HIV-RNA and CD4+ T cells count and lumbar puncture to quantify CSF HIV-RNA by the 
ultrasensitive Abbott RealTime HIV-1 assay (Abbott Laboratories) on frozen samples 
(lower detection limit of <40 copies/mL). Demographic, clinical and other viro-
immunological parameters were collected from the clinical records and the database of 
SPID cohort. 
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Performance of the “3 Questions Test” as a screening test of HIV-
Associated Neurocognitive Disorders: evaluation of Sensitivity, 
Specificity, Positive and Negative Predictive Value and association with 
Altered Quality of Life (3QT study). 
 
Introduction 
 
An adequate and reliable screening test for HAND is not yet available; thus, even if 
cognitive impairment in HIV-infected patients displays an unacceptable relatively high 
prevalence, these disorders are not routinely screened. In fact, several screening tools 
have been studied for HAND, but they display a low sensitivity and specificity in the 
range of 50-70%, in particular for milder forms of cognitive impairment, that are the 
prevalent ones nowadays[80, 165-167]. The overall performance of the available screening 
tests is thus not optimal and suggests the ongoing need for accurate and simple 
instruments to assess neurocognitive deficits in HIV-infected subjects.  
The European AIDS Clinical Society (EACS guidelines, version 9, October 2017) 
recommends that the “Three questions test” (3QT) may be used to guide physician to 
screen HAND in HIV-infected patients complaining of cognitive problems. This test, also 
called the Simioni Symptom Questions, had been proposed for the first time by Simioni 
S and colleagues; they found that patients complaining cognitive symptoms were 
affected by HAND in the 84% of cases, but 64% of patients with cognitive impairment 
were without complaints. As expected, the majority of “non complainers” subjects 
presenting HAND showed ANI[168].  
EACS guidelines suggest this screening test as the first approach in HIV-positive 
patients (Figure 3). After the exclusion of the confounding conditions, such as severe 
psychiatric illnesses, abuse of psychotropic drugs, alcohol abuse, sequelae from 
previous opportunistic infections of the CNS or other neurological diseases and current 
CNS infections or neurological conditions, the following simple 3 questions have to be 
asked to the patient: 
1. Do you experience frequent memory loss (i.e. do you forget the 
occurrence of special events, even the more recent ones, appointments, 
ect)? 
2. Do you feel that you are slower when reasoning, planning activities or 
solving problems? 
3. Do you have difficulties paying attention (i.e. to a conversation, a book or 
a movie)? 
For each question, answers could be: a) never, b) hardly ever, or c) yes, definitely. HIV-
positive persons are considered to have an “abnormal” result when answering “yes, 
definitely” on at least one question. If the test results “abnormal”, an evaluation for 
depression and its eventual treatment have to be considered. If the problem persists, 
even when depression has been excluded or optimally managed, patients undergo a 
complete neuropsychological examination. 
Neuropsychological evaluation will have to include tests exploring the following 
cognitive domains: fluency, executive functions, speed of information processing, 
attention/working memory, verbal and visual learning, verbal and visual memory, motor 
skills plus assessment of daily functioning through Instrumental Activities of Daily Living 
(IADL).  
The association between self-reported cognitive symptoms and objective neurocognitive 
impairment is still under debate; in fact, while few published works reported an 
association between self-reported complaint and overall cognitive performance 
assessed by neuropshychological evaluation, several studies did not find any 
association[169]. It has been hypothesized that the lack of association reflects the 
changes in the pattern of cognitive deficits in the recent years, especially in subjects 
with mild disorders, with a shift from the impairment in executive functions (reasoning) 
and working memory (attention) to poorer verbal learning related to patients reported 
memory problems. The reasons for the poor performance of subjective measures of 
cognitive function in the screening of objective cognitive deficits could be the over-
reporting of symptoms, the excessive subjective nature of some instruments, such as 
the 3QT, or the influence of depression and anxiety disorders[5]. 
 
Aim 
 
In this context, we hypothesized that the self-reporting 3QT is not reliable for the 
screening of cognitive disorders in patients with frontal and temporal cortex impairment. 
The aim of our work was thus to investigate the sensitivity, specificity, positive and 
negative predictive value of 3QT in a cohort of antiretroviral naive and treated HIV-
positive patients; we also explored factors associated with having an “abnormal” 3QT. 
 
Methods 
 
We conducted a cross-sectional study, including antiretroviral-naive and treated HIV-
infected people in active follow up at our centre (SPID cohort). 
Inclusion criteria were: 
 >18 years old 
 Antiretroviral-naive HIV-positive patients or HIV-positive patients on cART with 
any cART regimen 
 Comprehension and speaking of Italian language 
 Any CD4+ count and plasma HIV-RNA 
Exclusion criteria were: 
 Acute HIV infection 
 Current or sequelae of CNS Opportunistic Infections 
 Current alcohol or substance abuse 
 Cirrhosis 
 Current psychiatric or neurologic disorders 
After enrolment, patients underwent 3QT, a complete neurocognitive evaluation (11 
tests exploring 7 cognitive domains), performed by a trained neuropsychologist, SF-36 
Health Survey and Hospital Anxiety and Depression Scale (HADS) on the same day.  
Comorbidities were defined as cardiovascular risk factors (Framingham risk 
score>20%) or cardiovascular diseases, renal impairment (GFR<90 ml/min by CKD EPI 
equation) or history of malignancies. 
According to 3QT results, patients were divided in two groups: subjects with abnormal 
3QT (a3QT) if they answered “yes, definitely” to at least one question and patients with 
normal 3QT (n3QT).  
HAND was diagnosed according to the Frascati’s criteria (neurocognitive impairment 
was defined as 1 SD below the mean for demographically corrected norms over at least 
2 cognitive domains)[1]. We considered pathological a score >1 in the IADL, a score >11 
in the HADS and the norm-based pathological scores for MHI and PHI in the SF-36 
Survey (see section Materials and Methods). 
Sensitivity, specificity, positive and negative predictive value (PPV and NPV) were 
calculated with the standard methods in comparison with the reference diagnosis 
(patients with HAND).  
We considered a value of 80% as a good sensitivity and of 80% as a good specificity. 
We performed receiver operating characteristic (ROC) curve analyses to identify the 
predictive accuracy of the 3QT. The area under the curve (AUC) and the 95% 
confidence interval were calculated. Differences between groups were evaluated 
through Chi-squared test and Mann Whitney test, as appropriate. Factors associated 
with “abnormal” 3QT were investigated through univariable and multivariable logistic 
regression analyses. We also explored the association between altered quality of life 
assessed by SF-36 Health Survey and HAND. 
All the analyses were performed on the whole study population and on untreated and 
treated patients separately. Statistical analyses were carried out with SPSS software, 
version 21.0. 
 
Results 
 
Performance of 3QT in the study population 
We enrolled 302 HIV-infected patients; 191/302 (63%) were antiretroviral-naive 
subjects, 111/302 (37%) were on treatment. Table 1 shows demographic and viro-
immunological characteristics of study population. Median age was 44 (35-51) years 
and 244 (81%) were males. CD4+ T cells nadir was 311 (163-469) cells/mmc and 52 
(17%) subjects presented an AIDS-defining disease.  
99/302 (33%) of the patients presented an “abnormal” 3QT (a3QT), 82/302 (27%) 
showed HAND (Figure 9a-b). As regards quality of life, 121 (40%) and 52 (17%) 
patients displayed altered MHI and PHI, respectively; 38 (12%) were symptomatic for 
depression and 92 (30%) for anxiety. Among patients with HAND, we observed, as 
expected, a prevalence of mild forms of cognitive impairment: 71 (86%) cases of ANI, 
10 (12%) of MND and only 1 case (2%) of HAD (Figure 9b).  
Analyzing the performance of 3QT on the whole population, we observed that among 99 
patients complaining of cognitive decay, only 35 (35%) had HAND diagnosis; similarly, 
47/82 (57%) HAND diagnoses would have been missed relying only on 3QT (Figure 
9c). 
Sensitivity, specificity, PPV and NPV of 3QT resulted low and <80% in the population: 
sensitivity was 43% (32-53%), specificity 71% (65-77%), VPP 35% (26-45%) and VPN 
77% (71-83%). (Table 2). 
The ROC curve is presented in Figure 10: area under the curve (AUC) was 0,568, 
95%CI 0,494-0,642. Optimal cut off for 3QT cannot be investigated given the binary 
score of the test (normal/abnormal) and the lack of data regarding patients’ answers at 
each of the three questions of the test.  
Given that 3QT did not show an adequate sensitivity and specificity for the diagnosis of 
HAND, we asked which factors were associated with answering positively to the 3QT 
(a3QT). By fitting an univariable logistic regression analysis, females, heterosexual 
contacts, a longer time since HIV diagnosis, being on cART and comorbidities were 
associated with having a3QT. Furthermore, HAND, but also impaired SF-36 PHI and 
MHI and altered anxiety and depression scores by HADS resulted associated with 
a3QT. In the multivariable model, being on treatment was confirmed associated with 
a3QT; interestingly, HAND was not independently associated with a3QT, while SF-36 
PHI and MHI displayed, respectively, a 4- and 3-fold higher probability of a3QT (Table 
3).  
Performance of 3QT in untreated and on treatment HIV-infected patients 
We then explored the performance of 3QT in the group of untreated and on treatment 
patients separately. The population of untreated and on cART patients presented some 
differences that reflect the effect of antiretroviral treatment and the epidemiological 
characteristics of the SPID cohort. In fact, in comparison with treated HIV-infected 
patients, antiretroviral naïve subjects were younger, more frequently males and MSM. 
They were less commonly affected by HCV coinfection and other comorbidities. As 
regards HIV-related characteristics, untreated patients presented a shorter time since 
HIV diagnosis and a higher CD4+ nadir. 94 (85%) patients on treatment displayed 
undetectable plasma viral load (Table 1).  
Finally, untreated subjects also showed a lower proportion of a3QT, anxiety and 
depression symptoms and HAND (Table 1): prevalence of a3QT was 23% in untreated 
patients and 49% in treated subjects, HAND was found in 22% and 35% of antiretroviral 
naïve and on treatment patients, respectively. 
Sensitivity, specificity, PPV and NPV were confirmed low also dividing patients in 
antiretroviral naïve and on treatment subjects (Table 2). ROC curves are presented in 
Figure 11: AUC was 0,56, 95%CI 0,448-0,672 for untreated subjects and 0,543, 95%CI 
0,443-0,643 for patients on cART. 
In the group of untreated patients, we observed that a3QT was associated with female 
gender and impairment in PHI and MHI, performed by SF-36 survey. 
By fitting a multivariable analysis, antiretroviral naïve patients with altered SF-36 MHI 
presented a 2,3-fold higher probability of a3QT, adjusting for gender, SF-36 PHI and 
HAND (Table 4). 
No demographic and viro-immunological parameters were associated with a3QT in 
treated patients; in the univariable model, a higher reporting of anxiety, depression and 
altered physical and mental health were associated with a3QT. Adjusting for HAND, 
altered HADS anxiety and depression scores and SF-36 PHI and MHI, only SF-36 PHI 
remained independently associated with a3QT (Table 5). 
HAND was not associated with a3QT both in untreated and on treatment patients.  
 
Association between self-reported quality of life and HAND 
Given that the evaluation of quality of life by PHI and MHI of SF-36 Health Survey is 
more complete and detailed than the simple three questions of 3QT, we investigated if 
SF-36 Health Survey was associated with HAND; we found that altered PHI was 
associated with HAND in the study population (OR 2,17 versus normal PHI, 95%CI 
1,14-4,11, p=0,018) and in the subgroup of antiretroviral naïve patients (OR 2,5 versus 
normal PHI, 95%CI 1,07-5,85, p=0,034). Adjusting for age, months since HIV diagnosis, 
CD4+ nadir, plasma HIV-RNA, AIDS-defining diseases, hepatitis coinfection and 
comorbidities, PHI was not confirmed associated with HAND (AOR 2,63 versus normal 
PHI, 95%CI 0,85-8,1, p=0,09). No association between MHI and HAND was reported. 
Discussion 
 
Even if the need of screening for cognitive disorders in HIV-positive patients is more 
and more evident, a validate and accurate screening test for HAND is still not available. 
An adequate screening test would be useful especially for asymptomatic and mild forms 
of HAND, considering that they are associated with a decrease in the quality of life, 
reduced treatment compliance and increased mortality. Indeed, it is known that 
asymptomatic forms are at increased risk of future deterioration[89]. On the other hand, 
several risks in ascertaining ANI cases have to be taken into account, such as possible 
over-diagnosis, distress to asymptomatic individuals receiving a diagnosis, lack of an 
effective treatment and resources used for the detection of this disorder [81].  
The “Three Questions Test” is a screening test proposed by Simioni S et al and still 
recommended by EACS guidelines; its advantages are that is an easy-to-perform test, 
is very quick and could be administered by a physician without need of specific training 
or adjunctive costs. In the study by Simioni S et al, only cognitive complaint according to 
3QT was relatively predictive of HAND, but the negative result at the test did not rule it 
out; they however reported that the majority of non complainers presenting HAND had 
ANI[168].  
In our cohort we reported low performance of the “Three Questions Test” as a screening 
tool for HAND: both sensitivity and specificity resulted lower than 80% in a cohort of 
antiretroviral naïve and treated patients. In a previous study by Sacktor et al 3QT did not 
perform better (in detecting HAND the test had a sensitivity of 77.6%, a specificity of 
32%, a PPV of 69% and a NPV of 35%)[81]. One of the possible reason of the low 
accuracy of the 3QT could be that it is based on a very simple self-reported evaluation 
of cognitive symptoms; in previous works the association of HIV-associated cognitive 
impairment with self-reported cognitive symptoms was generally poor[5]. A dissociation 
between subjects’ self-complaint of neurocognitive impairment and objective 
performance was already found in a study by Hinkin and colleagues in 1996: in 46 HIV-
infected males that underwent a neuropsychological battery to investigate episodic 
memory, metacognition and depression, more than half of the patients presented a 
reduced awareness of their disorders reporting an impairment that exceeded memory 
testing’s deficits or denying impairment that was evident on memory testing [170]. Similar 
results were obtained also in a larger group of patients and with more complex 
evaluation of cognitive complaint: even the Cognitive Failures Questionnaire, a 25-item 
self-report questionnaire, failed to find an association between patient’s complaint and 
the objective results of the neuropsychological assessment, suggesting that 
asymptomatic HIV-infected subjects are not able to perceive their cognitive decline[171].  
On the contrary, using a self-report test that is very similar to 3QT, an association 
between self-reported cognitive functional status and objective neuropsychological 
performance was reported; this test, a simplified version of the MOS-HIV cognitive 
functional scale, includes 4 questions (how often during the previous 4 weeks: 1. Did 
you have difficulty reasoning and solving problems, for example, making plans, making 
decisions, learning new things? 2. Did you forget things that happened recently, for 
example where you put things, appointments? 3. Did you have trouble keeping your 
attention on any activity for long? 4. Did you have difficulty doing activities involving 
concentration and thinking?) and provides a measure of general health assessing 10 
specific dimensions of health. The authors found that this measure of cognitive 
functional status predicted overall neurocognitive performance assessed by a brief 
standardized battery in 85 HIV-positive males; however, not all enrolled subjects 
underwent the same complete neurocognitive evaluation and possible selection bias 
were reported: in fact, all subjects in this study were in the early phase of infection and 
volunteered to participate in a longitudinal research project that evaluated the effect of a 
supportive group program on clinical disease progression, suggesting that enrolled 
patients probable displayed a high grade of education. Furthermore, even if the authors 
hypothesized the use of the 4-item MOS-HIV scale for the screening of cognitive deficits 
after validation in larger cohorts, the sensitivity of this instrument for cognitive decline 
over time has to be ascertain[172]. We probably were not able to replicate the same 
association because of the larger number of enrolled patients, the less selection of 
patients (patients were consecutively enrolled in the study, including also individuals 
with low education and in the chronic phase of infection) and the easier nature of 3QT 
(results are not normally transformed as in MOS-HIV test). However, the previous work 
could suggest to investigate the utility of SF-36 Health Survey, that originated from 
MOS-HIV questionnaire, or a quicker form such as SF-12 survey as a screening test for 
HAND. In the work by Underwood J et al, both SF-36 summary score of mental and 
physical health were lower in patients with cognitive impairment than in subjects without 
deficits, but they were significant only for cognitive impairment identified with 
Multivariate Normative Comparison (and not for impairment defined by Global Deficit 
Scores or Frascati’s criteria)[169]. In our study, no association between SF-36 and HAND 
was found, but a study better designed for this outcome with the investigation of 
sensitivity and specificity of SF-36 Health Survey could provide more useful information.  
We described that self-reported mental and physical health measures are associate 
with having an “abnormal” 3QT, but both of this subjective evaluations are not 
associated with HAND in a cohort of antiretroviral naïve and on treatment patients. The 
association between SF-36 summary scores and positive 3QT reflects the subjective 
nature of these two tests.  
We also reported a probable influence of anxiety and depression symptoms in 
answering to 3QT, even if this association was not confirmed in multivariate analysis; 
similarly, previous works have underlined that depressive symptoms could affect both 
subjective and objective cognitive function and exclusion or optimal management of 
depression has always to be considered in diagnosing cognitive problems[5, 171].  
As already hypothesized by other authors, the lack of association between 3QT and 
HAND could be explained by an over-reporting of symptoms, also by patients that are 
not affected by objective cognitive impairment, the subjectivity of the questions 
regarding especially memory loss and the exploration of only some cognitive domains 
using these questions.  
Differences in neuropsychological performance between cART-naïve and experienced 
subjects may exist and thus we have performed the analysis also dividing the two 
groups of patients, but 3QT maintains a low accuracy in detecting objective cognitive 
impairment. 
Our study has some limitations: we have not included a group of HIV-seronegative 
control subjects and the cross sectional design of the study could not allow a 
prospectively assessment of the validity of this test. Information about comorbidities 
were obtained by clinical records, thus they could be underestimated due to missing 
data and this could have introduced confounders in the analysis. 
 
To conclude, the “Three Questions test” in our cohort showed a low sensitivity and PPV 
with a high number of false negatives both in antiretroviral-naïve and on cART patients, 
suggesting a lower self-awareness in patients with frontal and temporal cortex 
impairment and confirming the lack of association between subjective cognitive 
symptoms and objective cognitive impairment. The usefulness of this test as a 
screening tool for HAND should thus be revised. 
 
Oral presentation at 6 th International Meeting on HIV Infection of the Central Nervous 
System, Matera, Italy 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Less severe HIV-Associated Neurocognitive Disorders (HAND) are still 
common among antiretroviral (cART)-naive and cART-treated people 
living with HIV: association with not Italian origin, unemployment and 
non AIDS-related comorbidities (NeuroHIV Study) 
 
Introduction 
 
HIV-associated neurocognitive disorders (HAND) still affect 15-55% of HIV-infected 
patients and with the increased longevity of the HIV-infected population this prevalence 
is likely to increase[5]. While HIV-Associated Dementia (HAD) has declined, milder forms 
such as Asymptomatic Neurocognitive Impairment (ANI) and Mild Neurocognitive 
Disorders (MND) predominate and account for more than 70% of cases[28]. The 
persistence of these forms also in treated individuals could be explained by several 
factors: advancing age and the known lower cognitive reserve in older subjects, longer 
time since HIV diagnosis with the establishment of irreversible CNS damage prior to the 
cART introduction, persistent HIV viral replication and immune activation in the CNS 
despite effective control of replication in the plasma compartment, the presence of non-
infectious comorbidities and finally the toxic effect of some antiretroviral drugs[24, 99, 173]. 
One current matter of debate is the clinical impact of these mild forms of cognitive 
impairment, especially for the asymptomatic ones; previous works have demonstrated 
that these less severe disorders are still associated with a significant impairment in 
activities of daily living[27] and with an increased risk of evolution in more severe 
deficits[76]. Grant I and colleagues found that individuals with ANI from the longitudinal 
CHARTER cohort study display a three-fold higher risk of developing everyday life 
problems, compared to patients without cognitive impairment, and suggested that 
patients diagnosed with ANI deserve regular monitoring of cognitive status[28]. 
 
Aim 
 
We aimed to evaluate the prevalence and factors associated with HAND in a cohort of 
cART-naive and cART-treated HIV-positive patients. We also explored the modification 
of HAND after at least 12 months of virologically effective cART. 
 
Matherials and methods 
 
We conducted a cross-sectional study enrolling antiretroviral naïve and on cART HIV-
infected patients in active follow up at our Clinic. Exclusion criteria were:  
-the presence of neurocognitive comorbidities (brain injury, mental retardation, 
psychiatric disorders) 
-active alcohol or substance abuse 
-cirrhosis 
-not comprehension of Italian language.  
Patients underwent blood withdrawal to assess plasma HIV-RNA and CD4+ T cells 
count and a comprehensive neuropsychological evaluation including 11 tests that 
explore 7 cognitive domains to diagnose HAND according to the Frascati’s criteria[1]. 
Quality of life was assessed by self-reported SF-36 Health Survey and symptoms of 
anxiety/depression were investigated by Hospital Anxiety and Depression Scale (HADS) 
(see section Materials and Methods).  
A subgroup of cART-treated patients underwent also lumbar puncture to detect CSF 
HIV-RNA; we then identified patients with viral escape (VE), defined as CSF HIV-RNA 
>50 copies/mL when plasma HIV-RNA <50 copies/mL or CSF HIV-RNA ≥1log10 
copies/mL than plasma viremia[55].  
Comorbidities were defined as non-AIDS-related conditions: cardiovascular risk factors 
(Framingham risk score >20%), renal subclinical impairment (Glomerular Filtration Rate, 
GFR<90 ml/min by CKD EPI equation) and presence of malignancies. These data were 
collected from clinical records; Framingham risk score and CKD EPI equation were 
calculated using parameters measured in a range of 3 months since the 
neuropsychological evaluation. 
In a subgroup of unselected patients we perform also a longitudinal study: patients were 
re-evaluated after at least 12 months of virologically effective ART (T12) with the same 
neuropsychological battery.  
To explore factors associated with neurocognitive impairment in untreated and on cART 
patients and to take in account possible confounders we performed univariable and 
multivariable logistic regression models. Statistical analyses were carried out with SPSS 
software, version 21.0. 
Results 
 
Prevalence and factors associated with HAND in antiretroviral-naïve patients 
We enrolled 237 untreated patients; table 6 shows the baseline characteristics of the 
study population. Median age was 39 (IQR 32-47) years and 211 (89%) were males. 
Median time since HIV diagnosis was 2 (IQR 1-13) months and 42 (18%) subjects 
presented AIDS-defining diseases. Hepatitis C and B co-infection were found in 23 
(10%) patients and comorbidities in 41 (17%). Patients showed a median CD4+ count of 
368 (IQR 220-526) cells/mmc, while median plasma viremia was 4,71 (IQR 4,09-5,34) 
log10 copies/mL. 24 (10%) patients were not Italian and 19 (8%) were unemployed. 
62/237 (26%) patients presented HAND and the majority of subjects were diagnosed 
with mild forms of cognitive impairment (ANI in 93% and MND in 5%). HAD was 
reported only in 2% of subjects (Figure 12). 45 (19%) patients displayed impaired 
quality of life assessed by SF-36 Health Survey.  
In cART-naive patients, as expected, we found that patients with severe immune 
suppression presented a higher risk of HAND; in fact, in univariate anaylsis lower CD4+ 
T cells nadir and AIDS events were associated with HAND. Furthermore, we reported 
an association between HAND and non-Italian origin, unemployment, shorter duration of 
education and alterated SF-36 physical health score. By fitting a multivariable logistic 
regression analysis, HAND was independently associated with lower CD4+ nadir, non-
Italian origin and unemployment (the model was adjusted for age, months since HIV 
diagnosis, hepatitis coinfection, AIDS diseases, education and the presence of non 
infectious comorbidities) (Table 7).  
Prevalence and factors associated with HAND in cART-treated patients 
We enrolled 116 cART-treated patients: median age was 50 (43-56) years, most of 
them were males (81, 70%) and they showed a long history of HIV infection (median 
time since HIV diagnosis was 200, IQR 81-311 months). cART-treated patients were 
also characterized by a relatively advanced immune suppression: 29 (25%) subjects 
had AIDS-defining diseases and median CD4+ T cells nadir was 252 (IQR 150-399) 
cells/mmc. Patients presented a median plasma viremia of 3,26 (IQR 1,59-4,71) log10 
copies/mL; 27 (23%) displayed a detectable HIV-RNA. Hepatitis C and B co-infection 
were found in 50 (43%) patients and comorbidities in 41 (35%). Only 4 (4%) patients 
were not Italian and 16 (14%) were unemployed. 
HAND was found in 44/116 (34%) subjects: mild forms were the most prevalent ones 
(75% of ANI and 20% of MND), but, in comparison with untreated patients, we observed 
higher proportion of mild neurocognitive disorders (20% in treated versus 5% in cART-
naïve patients, p=0,004). Low prevalence of HAD was confirmed (5%) (Figure 12). More 
than half of the patients (54, 46%) reported an impaired QoL.  
39 patients performed also lumbar puncture and 7 (18%) had a viral escape. 
A higher probability of HAND was observed in patients with AIDS-defining conditions 
and detectable plasma HIV-RNA. We found also an association between cognitive 
impairment and the presence of comorbidities, unemployment and symptoms of 
depression. Conversely, no association with longer time on cART, CPE score and type 
of cART regimen was observed. In the multivariable model, adjusting for age, CD4+ 
nadir, AIDS diseases, hepatitis, years of education and employment, a longer length of 
HIV infection, the presence of comorbidities, symptoms of depression and the presence 
of detectable HIV-RNA were confirmed associated with a higher probability of cognitive 
impairment (Table 8). 
 
Longitudinal sub-study 
50 cART-naïve patients (with or without HAND at the first evaluation) repeated the 
complete neuropsychological evaluation after at least 12 months of virologically 
effective treatment (T12): 11 (22%) patients presented HAND (all cases of ANI). 33 
(66%) patients had a normal cognitive function both at enrolment and T12; among the 
17 patients presenting HAND at baseline, 8 (47%) subjects were improved from 
baseline and 9 (53%) maintain the same grade of cognitive impairment from baseline. 
10 treated patients (with or without HAND at the first cognitive assessment) were re-
tested at 12 months: in 6 subjects cART had been changed to a higher CPE score 
regimen at baseline and 7 underwent a second LP. In all subjects plasma and CSF HIV-
RNA were undetectable at T12. Half of these patients presented normal cognitive 
evaluation (5, 50%) and half presented ANI at T12 (5, 50%). 3 patients presented no 
cognitive impairment at baseline and at T12; among the 7 patients with HAND at 
baseline, 3 (43%) subjects displayed an improvement from baseline and 4 (57%) 
patients failed to restore their cognitive function. 
 
Discussion 
 
In our cohort of HIV-positive patients the prevalence of HAND is 26% in untreated 
subjects and 34% in cART-treated individuals; the prevalence rates of cognitive 
impairment in previous cohorts, usually assessed in antiretroviral treated populations, 
vary widely, probably due to differences in normative data sets, in the used definition of 
cognitive impairment and in the enrolment of asymptomatic or symptomatic patients [8, 
174].  
Our study adds information about the limited data regarding cognitive impairment in 
antiretroviral-naive subjects; in these patients we assessed cognitive performance in all 
subjects entering the study and not only in those with symptoms of cognitive 
impairment. 
Prior to the initiation of cART we found an association of traditional demographic and 
HIV-related risk factors with cognitive performance, as reported also by other cohorts: 
fewer years of education, low CD4+ T cells nadir and AIDS-defining diseases have 
been associated with poorer cognitive performance in several previous studies [19, 175-177]. 
We also reported an association between not Italian origin and cognitive impairment: all 
foreigner patients that have been enrolled in the study spoke and understood Italian 
language and thus were able to undergo the neuropsychological evaluation. We did not 
find a difference in years of education between Italian and not Italian patients (data not 
shown) and the association with cognitive performance was confirmed in the 
multivariable model, adjusting for education. The association with ethnicity has already 
been described previously and could probably be related to different cultural 
background and the lack of normative data for different ethnic groups, as suggested by 
Winston A et al[176, 178].  
Unemployed HIV-infected patients presented a higher risk of cognitive impairment: also 
in this case, possible confounders of this association have to be taken in account; a 
lower education was associated with unemployment in our cohort (data not shown), but 
surprisingly the association between unemployment and HAND was found also in the 
multivariable model after correction for years of education. 
However, in our cohort the number of non Italian and unemployed patients entering the 
study was limited and a possible interaction between these social factors, education and 
HAND has to be better explored.  
In cART treated patients we found a higher proportion of mild cognitive impairment, 
defined as MND by Frascati’s criteria, compared to untreated patients, probably 
reflecting the older age and a longer time since first HIV diagnosis of the cohort of 
treated subjects. We confirm the association of AIDS diseases, duration of known HIV 
infection and detectable plasma HIV-RNA with poorer cognitive performances, in line 
with other previous cohorts[7, 20, 21, 175, 177]. Current plasma viral replication could reflect 
poor cART adherence, that is another demonstrated risk factor for HAND[29]. The 
presence of non infectious comorbidities was associated with HAND: recently, MACS, 
CHARTER and other cohort studies have found a strong association between 
comorbidities, especially cardiovascular risk factors, and cognitive impairment [7, 21, 179-
181]. Regarding the association between symptoms of depression and HAND, we have 
to underline that in our cohort a small number of individuals reported depressive 
symptoms that were well-managed pharmacologically and none had a formal diagnosis 
of mild or severe depression. It has been widely demonstrated that depression could 
affect cognitive performance and mood disorders could be one of the causes or a 
consequence of cognitive impairment [23, 182].  
We did not find an association between cART regimen, duration of cART or CPE score: 
some previous reports have found that regimens yielded higher CPE values were 
associated with better neurocognitive outcomes, while others have found evidence of 
worse outcomes; disagreement between studies could reflect differences in study 
design and power account[99]. Furthermore, the role of antiretroviral neurotoxicity on 
cognitive function is still uncertain[183].  
Finally, the lack of association between HCV co-infection and HAND could instead 
reflect the successful treatment of HCV by Direct Acting Antivirals (DAAs). Unluckily, we 
have no data about plasma HCV-RNA in these patients at the moment of the 
neuropsychological evaluation, but most of them have probably already received 
antiviral treatment and reached undetectable HCV-RNA, reflecting the current 
guidelines. 
After one year of suppressive cART we did not observe modifications in the cognitive 
performance with the persistence of mild forms. The results from the MACS and 
CHARTER cohorts are similar and confirm that the majority of individuals with ANI, in a 
range between 61 and 77%, remain at the same HAND stage over a 4-year time 
period[12]. 
The limitations of this study are represented by the small number of patients enrolled, in 
particular in the longitudinal sub-study; however, our results confirm previous findings 
on larger cohorts. The presence of missing data about comorbidities and hepatitis 
coinfection’s treatment and the small numbers of foreigners, patients reporting 
unemployment and symptoms of depression and treated subjects with detectable 
plasma HIV-RNA could affect the associations reported in the multivariable analyses 
and thus have to be confirmed in larger cohorts of patients.  
 
In conclusion, we found a relatively high prevalence of asymptomatic forms of cognitive 
impairment in HIV-positive patients. The association of HAND with low CD4+ nadir, 
AIDS diseases and longer duration of infection supports the need of an early ART 
introduction, especially in foreigners and unemployed individuals. The control of 
peripheral viral replication, improving cART adherence, and the optimal management of 
comorbidities could probably prevent HAND in cART-treated patients. In a follow up 
period of ≥12 months of virologically suppressive cART, the majority of HAND cases 
seems to remain stable, suggesting that cognitive improvement requires a longer time 
or other approaches complementary to cART. 
 
Poster at 7th International Meeting on HIV Infection of the Central Nervous System, 
Pollenzo Italy, 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical and viro-immunological correlates of HIV-Associated 
Neurocognitive Disorders in a cohort of antiretroviral-naive patients 
(CSF/plasma HIV-RNA ratio study) 
 
Introduction 
 
HIV spreads early into the CNS, causing inflammation and HIV-associated 
neurocognitive disorders (HAND)[7, 35]. In untreated subjects HIV-associated dementia 
(HAD) currently represents a rare diagnosis, yet minor neurocognitive disorders affect 
30-35%[1, 8, 15, 184, 185] of patients.   
HIV per se plays a crucial role in the multifactorial pathogenesis of HAND[15, 16, 19, 43, 186-
188], however, while high CSF HIV-RNA levels feature subjects with HAD[50], studies 
have still to establish the precise link between CSF viral load and milder forms of 
HAND[14, 23, 52, 53, 189-191]. In this respect, also peripheral HIV replication has been 
described as a risk factor for cognitive impairment[7, 11] and the CSF/plasma HIV-RNA 
ratio was found to predict encephalitis better than CSF viral load[192]. Further, immune 
abnormalities both in the peripheral blood (a low CD4+ nadir [66], CD4/CD8 inversion[69, 
72], T-lymphocyte activation together with the shift from naïve to effector memory T-
cells[71]) and CNS (intrathecal immune activation[22, 58, 59, 193], activated T-lymphocytes 
and monocytes migrating to the CNS[66, 193]) have been associated with HAND.  
These findings suggest a complex relationship between viral burden and immune cells 
in the development of HAND and entail the need to identify markers other than CSF 
HIV-RNA for the management of this condition. 
 
Aim 
 
We explored the clinical and viro-immunological correlates of HAND in a cohort of 
untreated HIV-infected individuals. 
 
Methods 
 
We prospectively enrolled HIV-infected, antiretroviral-naive subjects at our centre. 
Exclusion criteria were: 
-the presence of neurocognitive comorbidities (brain injury, mental retardation, 
psychiatric disorders) 
-active alcohol or substance abuse 
-cirrhosis. 
Participants underwent simultaneous lumbar puncture and blood sampling to detect 
CSF and plasma HIV-RNA (ultrasensitive Abbott RealTime HIV-1 assay). The 
CSF/plasma HIV-RNA ratio was calculated as log10 CSF HIV-RNA divided by log10 
plasma HIV-RNA copies/mL. 
Peripheral T-cell activation and maturation subsets were measured by flow cytometry 
using the following fluorochrome-labeled antibodies: CD38-PE/CD45R0-APC-
H7/CD45RA-FITC/CD127-BV421/CD4-PerCPCy5.5/CD8-V450 (FACSVerse, BD 
Bioscience).  
A neuropsychological evaluation exploring seven cognitive domains was performed by a 
trained neuropsychologist within one month from enrolment. The Instrumental Activities 
Of Daily Living (IADL) and the Hospital anxiety and depression scale (HADS) were also 
assessed. HAND was defined according to the Frascati’s criteria[1] (see section 
Materials and Methods). Logistic regression analysis was used to identify the 
independent predictors of HAND. 
 
Results 
 
Study population 
189 HIV-infected individuals were enrolled. In our cohort, 18 participants (9%) were 
female and the median age was 39 (31-48) years. Of the 39 (21%) subjects presenting 
an AIDS-defining event, 3 had CNS involvement (neurotoxoplasmosis, cryptococcal 
meningitis) and thus underwent the neuropsychological evaluation upon complete 
resolution of the CNS diseases (i.e. >1 month from enrolment). The median time since 
HIV diagnosis was 2 (1-12) months. The median CD4+ nadir was 307 (126-443) 
cells/mmc with 60 (32%) subjects displaying <200 cells/mmc. The median plasma HIV-
RNA was 4.71 (4.09-5.34) log10 copies/mL, with CSF HIV-RNA values approximately 1 
log lower than those in plasma (3.63, 3.02-4.16 log10 copies/mL). The median 
CSF/plasma HIV-RNA ratio was 0.77 (0.61-0.92) and 30 (16%) subjects presented a 
ratio ≥1. 
 
Comparison between patients with HAND and subjects without cognitive 
disorders 
HAND was identified in 53 (28%) participants: 1 (2%) patient presented HIV-Associated 
Dementia (HAD), 10 (19%) a Mild Neurocognitive Disorder (MND) and 42 (79%) an 
Asymptomatic Neurocognitive Impairment (ANI). Subjects with HAND were comparable 
to those without cognitive defects in terms of age, sex, viral hepatitis co-infections and 
time since HIV diagnosis (Table 9). Patients with HAND more commonly presented 
AIDS-defining events and a lower CD4+ nadir. Of note, despite comparable median 
plasma and CSF HIV-RNA load as well as median CSF/plasma HIV-RNA ratio, the 
former were more frequently diagnosed with a CSF/plasma ratio ≥1. Further, subjects 
with HAND displayed higher CD8+, lower central memory CD127+CD4+ and naïve 
CD45RA+CD4+ T-cell percentages, compared to individuals without cognitive 
impairment. 
 
AIDS-defining diseases and CSF to plasma HIV-RNA ratio ≥1 were independently 
associated with HAND 
We next performed a multivariate logistic regression analysis to identify the independent 
predictors of HAND (covariates: AIDS, CD4+ nadir <200 cells/mmc, CSF/plasma HIV-
RNA ratio) and found that, both a diagnosis of AIDS and a CSF/plasma RNA ratio ≥1 
were associated with a 3-fold and 2.7-fold higher risk of HAND (respectively, AOR 
3.441, IC95% 1.38-8.58, p=0.008 and AOR 2.707, IC95% 1.122-6.531, p=0.027; Table 
10).  
 
Discussion 
 
The present study was conducted to explore the clinical and viro-immunological 
correlates of HAND in a cohort of HIV-infected, antiretroviral-naïve subjects, given the 
need, stemming from the controversial association between CSF viral burden and 
development of HAND, to identify possible novel markers of neurocognitive impairment 
in this setting. 
In our study, mild forms of HAND were reported in 28% of enrolled subjects and, in the 
univariate analysis, associated with AIDS, a CSF to plasma HIV-RNA ratio >1, a CD4+ 
T-cell nadir <200 cells/mmc and lower CD4+ naïve and central memory T-cells. In 
accordance with literature evidence suggesting a role of blood and CSF T-lymphocytes 
in the development of cognitive disorders in treated individuals [66, 71, 72], our findings put 
forward severe skewing of peripheral T-cell subsets as a pathogenic mechanism 
underlying minor forms of HAND in naïve subjects with advanced immune-depression[7, 
43]. Impairment of adaptive immunity in late stages of HIV disease may indeed favour 
viral penetration in the brain and trigger a neuroinflammatory response that drives 
cognitive defects in this setting[7, 43].  
The understanding of the precise mechanisms by which peripheral immune cells infect 
those residing in the CNS, hence generating compartmentalized viral replication is of 
interest also in light of the independent association we found, in the multivariate 
analysis, between HAND and a high CSF/plasma HIV-RNA ratio. The present finding 
highlights, in fact, the role of replication sources in the CNS rather than in plasma in the 
pathogenesis of minor forms of HAND in antiretroviral-naïve individuals. In contrast, we 
failed to observe a correlation between neurocognitive impairment and CSF HIV-RNA; 
this result may be explained by the general characteristics of our study population, 
which included subjects with minor forms of neurocognitive impairment [50, 194] and a 
moderate degree of immune-suppression[14].  
Adding to previous findings in mixed HIV settings, our research is novel in clearly 
identifying increased CSF/plasma HIV-RNA ratio as a predictor of HAND in a large 
cohort of untreated HIV-infected individuals. These findings set the basis for 
mechanistic investigation of HIV replication sources in the CNS, and, most importantly, 
put forward CSF/plasma HIV-RNA ratio as candidate biomarker to be used in the initial 
clinical assessment of antiretroviral-naïve patients, possibly guiding treatment and 
follow-up decisions.  
 
 
Research letter published in AIDS journal (Bai F, Iannuzzi F, Merlini E, Borghi L, Tincati 
C, Trunfio M, Bini T, d’Arminio Monforte A, Marchetti G, AIDS 2017; 31 (2):311-314. 
 
 
 
 
 
 
 
 
 
 
 
Peripheral and Cerebrospinal Fluid Immune Activation and 
Inflammation in Chronically HIV-Infected Patients Before and After 
Virally-Suppressive cART (Neuro MITO Study) 
 
Introduction 
 
While the current antiretroviral treatments of HIV infection have dramatically reduced 
the incidence of opportunistic infections [195-197], the onset of non-infectious co-
morbidities, such as cardiovascular, bone, renal and neurologic disease remains an 
issue in the everyday clinical practice [198-201]. 
HIV infects the central nervous system (CNS) within days of initial exposure and 
induces neuroinflammation that includes invasion of infected mononuclear cells and 
subsequent activation of localized inflammatory cells [202-204], possibly leading to 
neurocognitive decline [205, 206]. Many studies have investigated whether such an early 
seeding forms the basis for an independent viral replication in the brain, or whether the 
virus is cleared and penetrates at other points during the infection,without reaching a 
clear consensus [43, 203, 207, 208].  
Several authors have associated HIV-RNA levels in the cerebrospinal fluid (CSF) with 
the degree of HIV encephalitis (HIVE), cognitive impairment and severity of dementia 
[209-211]. Indeed, HIV viral load in the CSF has been generally considered a better 
predictor/correlate of neurocognitive impairment than HIV-RNA in blood [212, 213]. 
Interestingly, CSF/plasma HIV-RNA ratio has been recently demonstrated a better 
predictor of encephalitis and HIV-associated neurocognitive disorders (HAND) than 
CSF viral load alone [214, 215], leading us to assume a close interplay between the two 
anatomical compartments in the pathogenesis of neurological disorders in HIV infection. 
In support of this hypothesis, both peripheral and central immune impairment have been 
associated with HAND [57-59, 69, 72, 73, 115, 216-218]. 
The introduction of combination antiretroviral therapy (cART) resulted in a decline of 
HIV-associated dementia (HAD) [8, 143, 219] and a reduction of markers of intrathecal 
inflammation, such as neopterin and β-2 microglobulin [101, 220-223] and of active neural 
injury, such as neurofilament light chain protein (NFL) and tau protein [224-227]. However, 
the incidence of HIV-related mild, yet insidious forms of cognitive impairment persists 
with a significant impact on mortality and quality of life [8, 23, 139, 219, 228]. Partial 
explanation for the persistence of HAND despite successful cART may reside in the 
ongoing high levels of chronic systemic immune activation, associated with microbial 
translocation products and residual viral replication, sustained glia cell activation and 
markers of brain damage in the CNS of cART-treated individuals [223, 229-232]. Other 
potential mechanisms of pathogenesis include antiretroviral drug neurotoxicity, poor 
access of antiretroviral agents to the CNS, the legacy effect of CNS damage due to 
sustained HIV replication before cART initiation and indirect effects linked to aging and 
comorbid conditions, such as cerebrovascular disease and hepatitis C co-infection [8, 23, 
233, 234]. 
 
Aim 
 
Given our recent finding of an association between neurocognitive impairment and 
CSF/plasma HIV-RNA ratio [214], we wanted to assess whether HIV-infected patients 
with high CSF/plasma ratio (≥1) might display specific peripheral and/or CNS immune 
features, worthy of further investigation as possible players in promoting neurocognitive 
impairment. 
We therefore sought to explore a panel of peripheral and CNS inflammatory and 
immune activation markers in untreated HIV-infected patients and the effects of 12 
months of virally-suppressive cART, according to CSF/plasma HIV-RNA ratio. We also 
aimed at investigating whether specific peripheral and/or CNS immune features in HIV-
positive patients with diverse CSF/plasma HIV-RNA ratio might be associated with 
patients’ performance at neurocognitive screening tests. 
 
Materials and methods 
 
Study Population  
 
HIV-positive patients were consecutively enrolled at the Clinic of Infectious Diseases, 
University of Milan - ASST Santi Paolo e Carlo, Milan and at the Amedeo di Savoia 
Hospital, Turin (Italy) after providing written, informed consent. The study was approved 
by the Ethical Committees of both hospitals. Inclusion criteria were:  
-age >18 years old 
-naïve to cART  
-sufficient knowledge of Italian language to undergo neurocognitive evaluation.  
Exclusion criteria were:  
-past and/or current presence of psychiatric or neurological diseases,  
-drug/alcohol abuse  
-CNS opportunistic infections in the 6 months prior to the enrollment 
-cirrhosis.  
HIV-positive patients underwent lumbar puncture and blood sampling prior to cART (T0) 
and after at least one year of therapy (T12).  
Patients were stratified according to CSF/plasma HIV-RNA ratio in:  
(i) CSF/plasma HIV-RNA <1, defined as Low Cerebrospinal Fluid (L-CSF)  
(ii) CSF/plasma HIV-RNA ≥1 defined as High Cerebrospinal Fluid (H-CSF). 
Neuropsychological Assessment  
 
The presence and the severity of depression were assessed through the Beck 
Depression Inventory-II (BDI-II) and we excluded from the study patients with severe 
depression (score ≥30). A short screening neurocognitive battery, consisting of Mini 
Mental State Examination (MMSE)[79], Frontal Assessment Battery (FAB)[235] and 
International HIV Dementia Scale (IHDS)[85, 86], was administered by a physician to 
explore the cognitive performances at T0 and T12 in an unselected subgroup of 
patients. A pathological neurocognitive performance was defined as at least one altered 
test. 
Plasma and CSF Immune Activation/Inflammation Markers 
 
Plasma levels of sCD14, IL-6, TNF-α and IFN-γ were quantified by commercially 
available ELISA assay (R&D Systems), according to the manufacturer’s protocol. CSF 
levels of IL-6, TNFα, sCD14, MCP-1 and IP-10 were measured by LUMINEX 
technology (R&D Systems), whereas CSF levels of Neopterin and S100β were 
measured by commercially available ELISA assay, according to manufacturer’s 
instructions (IBL international; ALPCO). 
 
T-Cell Immune Phenotypes 
 
T lymphocyte surface phenotypes were evaluated on cryo-preserved samples by flow 
cytometry. The following fluorochrome labeled antibodies were used: CD4 PE-Cy7, CD8 
PE-Cy5, CD38 PE, CD45R0 APC, CD45RA FITC, CCR7 PE, HLA-DR FITC and Ki67 
FITC (BD Biosciences). The following combination of antibodies were used: CD8 
/CD4/CCR7/CD45RA (maturation), CD8/CD4/CD38/HLA-DR/CD45R0 (activation), 
CD8/CD4/Ki67 (proliferation). For the evaluation of the intracellular Ki67 a 
fixation/permeabilization step was required. Cell viability was assessed by 7-
aminoactynomycin D (7-AAD; BD Biosciences): only samples with viability greater than 
70% were used for the experiments. 
 
PBMC stimulation  
 
Cryo-preserved PBMCs (1x106) were thawed and incubated in the presence of a pool of 
gag-env peptides (5uM), or CMV (2 μg/mL,) or Staphylococcal Enterotoxin B (2,5 
μg/mL) as positive control. Brefeldin A (10 μg/mL, Sigma-Aldrich) and the co-stimulatory 
antibodies CD28 (1 ug/ml, Becton Dickinson) were added and cells were incubated over 
night at 37°C with 5% CO2.  
 
Intracellular cytokine staining 
 
Cells were harvested and stained with CD8 PE-Cy5 and CD4 PE-Cy7 (Beckman 
Coulter). After PFA fixation (1%, Sigma-Aldrich), cells were permeabilized with Saponin 
0.2% (Sigma-Aldrich) and stained with IL-2 PE and IFNg FITC (Beckman Coulter) for 
30min at RT. The values of IL-2 and IFN-γ assessed in medium alone were subtracted 
from SEB, HIV or CMV stimulation to reduce any possible bias due to the experimental 
procedure.  
 
Total HIV-DNA detection 
 
A pellet of 1x106 PBMC were digested with lysis buffer over/night at 55°C and the lysate 
was used directly in a nested PCR in order to quantify both HIV and CD3 gene copy 
numbers, as previously described. 
 
Statistical Analysis 
 
Continuous variables were expressed as median and interquartile range (IQR), whereas 
categorical variables were expressed as absolute numbers and percentages. The 
groups of patients and the different time points were compared using Chi-square or 
Fisher’s exact test, Mann-Whitney, Kruskal-Wallis or Wilcoxon paired test as 
appropriate and the correlations among variables were tested by Spearman Rank 
correlation’s coefficient. p values <0.05 were considered statistically significant. Data 
were analyzed with GraphPad 5 Prism (GraphPad Software Inc).  
 
Results 
Patient population at baseline 
We enrolled 70 HIV-infected antiretroviral-naive patients, stratified according to the 
CSF/plasma HIV-RNA ratio (see material). 61/70 (87%) were L-CSF, whereas 9/70 
(13%) were H-CSF.  
Figure 13 shows patients’ assignments to peripheral blood (PB) and CSF analyses and 
to neurocognitive screening tests.  
H-CSF group featured lower CD4 count and CD4/CD8 ratio at time of analysis, as 
compared to L-CSF group (Table 11). As per definition, H-CSF showed lower plasma 
HIV-RNA levels and higher CSF HIV-RNA levels, yet similar peripheral total HIV-DNA 
(Table 11). No other differences were found among the two study groups.  
We found a positive correlation between plasma and CSF HIV-RNA (r=0.34, p=.004), 
and between CSF HIV-RNA and total plasma HIV-DNA (r=0.43, p=.027) . 
 
Baseline peripheral and CNS immunological features of L-CSF and H-CSF 
patients 
Before cART initiation, L-CSF and H-CSF patients showed comparable levels of 
peripheral T-cell activation, proliferation and maturation, as well as HIV- and CMV-
specific response (Table 12). Interestingly, the baseline frequency of circulating 
activated HLA-DR+CD38+CD8+ positively correlate with both CSF and plasma HIV-
RNA (CSF: r=0.35, p=.046; plasma: r=0.53, p=.005 Figure 14a-b).  
At baseline, L-CSF and H-CSF displayed comparable levels of pro-inflammatory 
markers both in peripheral blood (i.e. IL-6, TNF-α, sCD14, IFN-ỿ: Table 12) and in CSF 
(i.e. sCD14, IL-6, TNF-α, MCP-1, IP-10, neopterin, Table 13).  
Interestingly, we did find a positive association between CSF HIV-RNA and intratechal 
pro-inflammatory markers (IL-6: r=0.39, p=.004; MCP-1: r=0.30, p=.031; IP-10: r=0.31, 
p=.033; neopterin: r=0.35, p=.005; Figure 14c-f).  
 
Peripheral and CSF viro-immunologic parameters in H-CSF and L-CSF following 
12 months of cART.   
In an unselected subgroup of 33/70 HIV-positive patients (26 L-CSF and 7 H-CSF) who 
agreed to undergo CNS and blood sampling after 12 months of cART, we investigated 
the effect of virally-suppressive cART on markers of immune activation/inflammation 
according to CSF/plasma HIV-RNA ratio (Figure 13). No differences in cART regimens 
between L-CSF and H-CSF patients were reported (Figure 15a). As expected, in both 
groups we observed viral suppression, with all patients reaching undetectable plasma 
and CSF HIV-RNA despite stable total HIV-DNA, and a parallel rise in CD4 count and in 
CD4/CD8 ratio (Figure 15a).  
i) Peripheral blood pro-inflammatory cytokines 
Upon 12-month cART, HIV-infected patients as a whole significantly reduced 
plasma TNF-α (p=.008; Figure 15b), with no other differences following cART 
introduction (Figure 15b-e). Similarly, following the stratification of patients according to 
CSF/plasma HIV-RNA ratio, only L-CSF group showed a reduction of circulating TNF- α 
(p=.048; Figure 15b).  
ii) T-cell activation and maturation  
At T12, HIV-positive patients significantly reduced activated CD38+CD8+ 
(p<.0001, Figure 15f) and memory activated CD38+CD45R0+CD8+ (p<.0001; Figure 
15g). In particular, H-CSF and L-CSF significantly reduced the proportion of 
CD38+CD8+ to a median of 2% (IQR 2-3) (p=.063, p=.003 respectively; Figure 15f) and 
the proportion of CD38+CD45R0+CD8+ to a median of 1% (IQR 1-2) (p=.062; p=.003 
respectively; Figure 15g). Similarly, we observed a non-significant decrease in HLA-
DR+CD38+ CD4 (H-CSF: 3.3% [1.03-6.85]  vs 1% [0.30-1.87] p=0.13; L-CSF: 1.90% 
[0.98-5.05] vs 1.80% [0.50-2.56], p=0.57) and CD8 T-cells (H-CSF: 8.35% [5.58-18.55] 
vs 3.48% [2.30-5.22] p=0.25; L-CSF: 8.35% [4.45-13.73] vs 3.42% [1.20-8.97] p=0.32) 
in both study groups. No differences in proliferating Ki67-expressing T-cells were found 
neither in HIV+ patients as whole nor in H-CSF and L-CSF, following 12 month of cART 
(data not shown).  
With regard to T-cell maturation, in HIV+ patients as a whole we observed 
increased proportion of naïve CCR7+CD45RA+CD8+ (p=.022; Figure 16d), with a 
decrease in effector memory CCR7-CD45RA-CD8+ (p=.007; Figure 16d).  
Stratifying the patients according to CSF/plasma HIV-RNA ratio, we found that while H-
CSF did not show any modification following cART introduction (figure 16b, 16e), in L-
CSF 12 months of cART partially redistributed naïve and memory T-cell subsets. 
Indeed, L-CSF significantly increased the proportion of naïve CCR7+CD45RA+CD4+ 
and CCR7+CD45RA+CD8+ (p=.044; p=.005 respectively; Figure 16c, 16f) and central 
memory CCR7+CD45RA-CD4+ (p=.005; Figure 16c) and significantly reduced effector 
memory CCR7-CD45RA-CD8+ (p=.018; Figure 16f). Moreover, at T12, L-CSF showed 
higher proportion of central memory CD4+ (p=.054) and lower proportion of effector 
memory CD8+ (p=.045) as compared to H-CSF. 
iii) Intracellular Cytokine production following HIV and CMV challenge 
We next assessed HIV- and CMV-specific intracellular IL-2 and IFN-ỿ production 
(see Figure 17a for flow cytometry profiles of cytokine-producing CD4 T-cell 
distribution).  
The percentage of both HIV- and CMV-specific single-positive IL-2+CD4+ significantly 
decreased following cART introduction in HIV+ patients as a whole (p=.008, p=.001, 
respectively, Figure 17b-e) as well as in L-CSF group (p=.007; p=.001; respectively, 
Figure 17b-e), with no changes in IFN-ỿ and IL-2/IFN-ỿ producing CD4+ (Figure 17b-e).  
No major differences in HIV- and CMV-specific CD8+ response were observed before 
and after cART introduction in both L-CSF and H-CSF (Figure 18). 
iv) CSF pro-inflammatory markers  
In HIV-infected patients as a whole, cART was efficacious in reducing CSF pro-
inflammatory cytokine/chemokine levels, reaching significance for sCD14 (p=.001; 
Figure 19a), IL-6 (p=.025; Figure 19b), MCP-1 (p=.012; Figure 19d) and IP-10 (p=.014; 
Figure 19e). Interestingly, following cART introduction, only L-CSF patients significantly 
contracted sCD14 (p=.006, Figure 19a), IL-6 (p=.037, Figure 19b) and MCP-1 (p=.017, 
Figure 19d). 
No significant differences in pro-inflammatory TNF-α, IP-10, neopterin as well as 
in astrocyte damage marker S100beta were found in both H-CSF and L-CSF following 
12 months of suppressive cART (Figure 19c,e-g).  
 
Neurocognitive performance in H-CSF and L-CSF before and after 12 months of 
cART.  
An unselected group of 22/33 patients (16 L-CSF and 6 H-CSF subjects) were 
willing to undergo a neurocognitive evaluation at baseline and after 12 months of 
virologically-effective cART (see Figure 13). At baseline, 9/22 subjects presented 
altered neurocognitive evaluation: 5/16 (31%) L-CSF, 4/6 (67%) H-CSF; p=0.178. 
Following 12 month of suppressive cART, we failed to observe significant changes in 
neurocognitive performance with persistent neurocognitive deficits in 4/16 (25%) L-CSF 
and 4/6 (67%) H-CSF (p=0.137). 
In this subgroup of patients, both peripheral and CSF markers paralleled the 
trends described in the longitudinal population of 33 patients. Indeed, at T12 only L-CSF 
patients significantly decreased circulating pro-inflammatory markers and the proportion 
of activated T-cells, with a partial redistribution of naïve/memory CD8 T-cell subset 
(Table 14). Similarly, CSF inflammatory markers such as MCP-1 and IP-10 significantly 
diminished following 12 months of cART only in L-CSF (Table 15). At the opposite, no 
significant changes in circulating and CSF immune activation/inflammation were evident 
in H-CSF (Table 15). 
 
Discussion 
We have recently demonstrated that a CSF/plasma HIV-RNA ratio of at least 1 
was independently associated with HIV-associated neurocognitive disorders (HAND), 
after adjustment for CD4 nadir, suggesting a role for active CNS viral replication in the 
pathogenesis of neurocognitive impairment[214]. Nonetheless, whether and how the 
presence of a high CSF/plasma HIV-RNA ratio is linked with specific immunological 
alterations in both systemic circulation and CNS is still under investigated. 
Hence, this study aimed to explore (i) a panel of peripheral and central immune 
activation/inflammation markers in HIV-infected untreated patients with high and low 
CSF/plasma HIV-RNA ratio, (ii) the effects of 12 months of suppressive cART and (iii) 
the possible associations between peripheral/CNS immune features and neurocognitive 
performance at a first-line/screening neurocognitive assessment. 
In our cohort, we found that 13% (9/70) of patients displayed a CSF/plasma HIV-
RNA ratio≥1, possibly reflecting a compartmentalization of the virus that actively 
replicates in the CNS[202]. Research investigating the pathways underlying 
neuropathogenesis suggest the mixed contribution of both free virus and cell-mediated 
HIV entry, seemingly dependent on the precocity of HIV infection: in earliest infection, 
HIV seems to mainly invade the CNS through circulating infected cells[203, 236], whereas 
during chronic infection the virus might freely pass into the CNS, as consequence of 
inflammation-mediated damage of BBB integrity. In such context, our finding of a 
positive association between CSF and plasma HIV-RNA irrespective of CSF/plasma 
ratio coupled to the association between CSF HIV RNA and CSF pro-inflammatory 
cytokines, would altogether lend support to passive viral flow from blood to CSF, 
through a highly damaged blood-brain barrier rather than active in situ replication[204, 236] 
in our cohort of chronically-infected patients. In fact, previous data have shown an 
association between BBB altered permeability and markers of neuronal damage and 
astrocytosis, in late presenter cART-treated subjects with suppressed CSF HIV 
RNA[237]. Nonetheless, we did not find any association with S100beta possibly reflecting 
the earlier diagnosis and treatment of our cohort. In our cohort of chronically HIV-
infected antiretroviral-naïve patients, we hereby describe similar levels of CNS and 
peripheral immune activation, function and inflammation irrespective of the levels of 
CSF/plasma HIV-RNA ratio, pointing to a well-established disruption of blood-brain 
barrier[238], in sharp contrast with data by Spudich et al[31], showing signiﬁcantly lower 
CNS inflammation in acutely HIV-infected patients with minimal CSF HIV-RNA 
replication (CSF HIV-RNA<100 cp/ml) compared to participants with higher intrathecal 
HIV-RNA. 
Along with the expected decline of both plasma and CNS HIV-RNA, 12 months of 
virally-suppressive cART, resulted in a reduction of peripheral and CNS immune 
activation and inflammation in the entire cohort, with no recovery of HIV/CMV-specific 
polyfunctional IL-2/ /IFN-secreting T-cells, in line with the massive impairment of T-cell-
mediated control of chronic viral infections[239-241]. Interestingly, following 12 months of 
virally-suppressive cART, while L-CSF patients partially restored peripheral and CNS 
immune activation/inflammation, individuals with high CSF/plasma HIV-RNA ratio 
maintained a skewed T-cell homeostasis, toward a more effector/exhausted immune 
phenotypes and failed to reduce intrathecal inflammatory levels. The persistence of 
disrupted T-cell homeostasis and function and of a pro-inflammatory milieu in the 
systemic circulation, are highly likely to impair immune patrolling over HIV, possibly 
favoring CNS virus entry and further exacerbating neuro-inflammation and damage, as 
clearly indicated by persistently heightened levels of pro-inflammatory mediators in the 
CSF of these patients. At the opposite, HIV+ individuals featuring low CSF/plasma HIV-
RNA ratio showed a trend toward recovered peripheral and CNS immune abnormalities, 
supporting the hypothesis that HIV+ individuals with low viral burden, by achieving and 
maintaining a better viral suppression, possibly prevent further injurious CNS 
processes, including viral invasion, cellular trafficking, and immune activation [204, 222]. 
Another possible explanation of the observed amelioration may reside in the more 
preserved immune competence at baseline. Indeed, the higher CD4 count and 
CD4/CD8 ratio might explain why L-CSF partially recovered peripheral and CNS 
immune abnormalities; this could also probably suggests that H-CSF patients might 
benefit of a cART regimen with a higher neuropenetration or might not be the best 
candidates for simplification strategies. 
Lastly, we asked whether CSF and peripheral activation and inflammation might be 
associated to neurocognitive impairment as assed by first-line neurocognitive evaluation 
in our cohort of chronically-infected individuals. Previous studies have demonstrated 
higher CSF and peripheral HIV-RNA levels, as well as activation/inflammation markers 
in individuals with HIV-associated neurocognitive disorders as compared to individuals 
without dementia [116, 211, 242-246], demonstrating the pathogenic role of HIV virus and 
immune activation in shaping neurocognitive outcome.  
In our cohort, while the proportion of individuals with neurocognitive impairment 
assessed by a short battery of screening tests was higher in H-CSF (67%) than L-CSF 
patients (31%), this did not reach statistical significance possibly due to a small number 
of subjects in study. Most interestingly, after 12-months suppressive cART, H-CSF 
patients, while failing to contain intratechal pro-inflammatory burden, did not show a 
worsening in cognitive performance as assessed by screening tests, possibly 
suggesting that longer exposure to high intrathecal viral load is required to induce 
cognitive decline as previously shown by Ellis et al [212].  
We should acknowledge that the screening neurocognitive battery used in this study 
consent the sole identification of patients with high degree of cognitive decline and is 
not powerful enough to highlight more subtitles disorders. However, a short screening 
cognitive battery has the advantage of being easier to perform allowing the 
administration by physicians during routine visits, instead of a complete 
neuropsychological evaluation that is time- and resource-consuming and needs a 
trained neuropsychologist, and is supported by both Italian and EACS guidelines [247, 
248]. Given the lack of a validated and universally accepted screening battery, we 
decided to use IHDS and MMSE, two of the first published screening tools for HIV-
Associated Dementia, that have been used more generally for HIV-associated 
neurocognitive disorder in several previous studies [79, 86], coupled with FAB, that has 
been recently associated with high specificity [235, 249]. Despite the efforts in validating 
the clinical use of both IHDS and MMSE as screening for HAND, a clear consensus is 
still lacking, with no other options than combine different tests, in order to gain more 
accuracy and reliability. This absence of a complete battery of neuropsychological test 
might have prevented us from finding associations between CSF inflammation and 
neurocognitive performance. 
Other caveats in the experimental design of the present study must be 
acknowledged including (i) the limited sample size for the group of H-CSF patients and 
for the longitudinal analysis that might have influenced the statistical power, (ii) the 
absence of a cART follow up longer than 12 months and (iii) the lack of a direct BBB 
damage marker. 
In conclusion, CNS damages persist even in HIV+ individuals on virally-effective cART 
[205, 222] through mechanism(s) still poorly understood. 
Aside from immune activation/inflammation and HIV viral load, other conditions are now 
emerging in the setting of long-term survival with chronic HIV infection that may 
influence the integrity of the CNS and the subsequent cognitive impairment. In 
particular, accelerated/premature aging and cardiovascular risk factors, such as 
hyperlipidemia, hypertension and carotid intima-media thickness have been recently 
identified as associated with reduced neurocognitive performance in HIV infected 
subjects [250-252].  
To our knowledge this is the first study trying to explore the association between both 
peripheral and CNS inflammation/activation and neurocognitive screening tests.  
Although the nature of our study did not allow us to find a “cause and effect” 
relationship, our observations that HIV+ patients with high CSF/plasma HIV-RNA ratio 
are not able to reduce and contain both peripheral and central pro-inflammatory/effector 
phenotypes despite suppressive cART, might point to the need of a closer follow-up of 
these subjects and strongly support the urgency of early treatment, in order to rapidly 
and massively reduce CNS viral burden, in turn limiting the neuroinflammation and 
neurotoxicity. These data may provide the rationale to use CSF/plasma HIV-RNA ratio 
as biomarker for monitoring and possibly identifying patients that maintain higher CNS 
pro-inflammatory milieu and that for this reason might be at higher risk of neurocognitive 
impairment. 
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Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive 
Disorders: Case Reports of A New Computer-Based Restorative Approach 
In 3 HIV-Positive cART-Treated Patients 
 
Introduction 
 
HIV-infected patients undergoing long-term cART present an increased risk of morbidity  
and mortality in comparison to HIV-negative individuals due to clinical complications 
typically associated with aging, including cardiovascular disease, cancer, osteoporosis 
and cognitive impairment[253]. HAND, that is still a relatively common problem in the 
management of HIV-infected patients, is characterized by impairments in several 
cognitive domains leading to poor cART adherence, regardless of other 
neuropsychiatric factors[254]. Considering the consequences of HAND, novel strategies 
to handle cognitive impairment still remain an unmet clinical need and should be a 
priority. 
Due to the lack of an optimal pharmacotherapy for HAND, researchers have 
investigated the possibility of cognitive rehabilitation. In the last years pilot studies 
investigating computerized rehabilitation on HIV-infected patients have been 
published[148-150]: all these studies have adopted a restorative approach. Even if their 
outcome was not the resolution of HAND, but the improvement of specific 
neurocognitive functions, their initial results were encouraging. Given a recent report by 
Livelli et al[154] showing the efficacy and stability over time of a cognitive rehabilitation 
protocol in treated HIV-positive patients with HAND, we hereby describe our experience 
on the efficacy of a new computer-based program in 3 HIV-positive patients on cART. 
 
Aim 
 
We investigated the efficacy of a new computer-based program in improving cognitive 
functioning in 3 HIV-infected patients on stable effective cART. 
 
Materials and methods 
 
We consecutively enrolled 3 HIV-positive patients on stable cART from a larger cohort 
who underwent a complete neuropsychological battery in the context of a dedicated 
outpatient service for the diagnosis and follow-up of HAND. Inclusion criteria were: 
-≥ 18 years of age 
-history of HAND according to Frascati’s criteria[1] 
-being on stable cART (>6 months) with plasma HIV-RNA <40 UI/ml, regardless of 
CD4+ T-cells.  
Exclusion criteria were: 
-history of CNS diseases and psychiatric disorders 
-drug addiction or alcohol abuse in the last 12 months. 
The Institutional Review Board approved the study and all the patients signed a written 
informed consent. At enrolment (T0), the patients underwent a complete 
neuropsychological battery composed by tests covering seven different cognitive 
domains. The functional assessment was evaluated through the instrumental abilities in 
daily living (IADL) and Short Form-36 (SF-36) for quality of life; anxiety and depression 
symptoms were explored by the Hospital Anxiety and Depression Scale (HADS) (see 
section Matherials and Methods). Frascati’s criteria were used for the diagnosis of 
HAND[1]. 
The patients underwent 12 sessions of a computer-based rehabilitation program, a 
novel brain plasticity-based computerized cognitive training 
(https://dynamicbrain.brainhq.com/), adopting a restorative approach. Previous studies 
demonstrated the efficacy of this program in improving generalized measures of 
memory and attention and in maintaining long-term effects among the elder general 
population[255, 256]. Given these encouraging data, the neuropsychologist selected a 
panel of exercises from the training program; the selected exercises stimulated the skills 
of the cognitive domains that are most frequently impaired in HAND[1]. The 17 selected 
exercises were: divided attention, target tracker, double decision, mixed signals, freeze 
frame, hawk eye, visual sweeps, eye for detail, memory grid, scene crasher, syllable 
stacks, face facts, card shark, juggle factor, right turn, mental map and optic flow. Each 
exercise was automatically administered in different steps with progressively increasing 
difficulty. Each session lasted one hour once a week for three months and it was 
performed under the supervision of a physician. The physician scheduled each session 
according to patient’s availability, helped patients to use the program and explained how 
to perform the exercises. Two weeks after the end of the program (T1), the patients 
were re-tested with HADS, IADL, SF36 and the same neuropsychological battery using 
parallel forms for those tests which test-retest reliability is over three months, in order to 
control for the potential confounding ‘practice effect’. 
Results 
 
All patients were Caucasian males; two patients had previous AIDS-defining events 
without central nervous system involvement. One subject had diabetes mellitus with 
good glycemic control on oral hypoglycemic therapy; no other known comorbidities, 
including viral hepatitis co-infection, were present. Table 16 shows features of the 
performances at T0 and T1 for each patient. Table 17 shows the functional assessment 
for each patient at T0 and T1. 
Patient 1 was 58 years old; at the time of examination CD4+ T-cells were 405/mmc, 
with undetectable HIV-RNA. Nadir CD4+ T-cells was 5/mmc. Time from the first HIV 
diagnosis was 174 months and the patients was on cART for 173 months. At T0 the 
patient complained of cognitive decline and he was diagnosed with MND: he showed 
deficit in two different cognitive domains (attention/working memory and motor skills) 
and an altered IADL score. After 12 weeks of cognitive rehabilitation (T1) the patient 
improved, according to Frascati’s criteria: only one cognitive domain (motor skill) 
remained altered. He also presented a normal IADL and HADS anxiety score. 
Patient 2 was 40 years old; he presented a CD4+ T-cells count of 366/mmc with a 
CD4+ T-cells nadir of 183/mmc and a HIV-RNA <40 UI/ml; time from the first HIV 
diagnosis was 14 months, while cART duration was 12 months. He had ANI at T0: two 
different cognitive domains were altered (memory and executive functioning) in absence 
of symptoms. At T1 he restored normal neurocognitive performance, reaching the 
normal equivalent score in each neuropsychological test. 
Finally, patient 3 was 36 years old with CD4+ T-cells of 522/mmc, CD4+ T-cells nadir of 
96/mmc and HIV-RNA <40 UI/ml. Time from the first HIV diagnosis was 19 months and 
he was on cART for 15 months. This patient complained of cognitive decline and 
displayed a diagnosis of MND at T0: he had deficits in 3 different cognitive domains 
(speed of information processing, motor skills and executive functioning) and an altered 
IADL score. At T1 the patient improved reaching normal performance according to 
Frascati’s criteria: he showed only one altered domain (speed of information pro-
cessing), without symptoms, and he had normal IADL score. Moreover, patient 3 had an 
improvement of SF36 score. Patients’ adherence to the program was 100%. 
Discussion 
 
The absence of an effective treatment for HAND has led researchers to explore 
cognitive and behavioral approaches. The neuro-rehabilitation is known to be useful in 
the management of other forms of dementia, like Alzheimer’s and Parkinson’s disease, 
and to prevent senile cognitive decline[257]. Typically, the cognitive rehabilitation 
approaches are divided in two categories: restorative and compensatory. Compensatory 
rehabilitation aims to minimize the cognitive deficits by helping the patient to develop 
and learn new strategies to overcome the impairment (i.e. people with poor memory can 
have a small slip to write down what they need to remember). The compensatory 
approach is mainly used for rehabilitating deficits after a stroke or a traumatic brain 
injury, by stimulating perilesional or controlateral homologous areas and their 
corresponding functions. Restorative approaches rely upon the principle of neuro-
plasticity and propose that “drill-and-practice” of cognitive skills will encourage more ef-
fective neural organization and ultimately improve impaired cognitive abilities. In fact, 
restorative rehabilitation aims to enable people to develop the lost function through 
specialized computerized and manual cognitive exercises. 
All three previous pilot studies investigating cognitive rehabilitation on HIV-infected 
patients adopted a restorative approach[148-150], while Livelli at al. used a compensatory 
approach[154]. In our study we chose the brainHQ program (Posit Science Inc, San 
Francisco, US), a restorative approach tool, given previous data in preventing senile 
cognitive decline in a long time follow-up[257]. Furthermore, this program is available in 
eight different languages and can therefore be reproduced in different geographical 
settings.  
In the previous studies on HIV-positive patients, the interventional program was self-
administered at the research center or at patient’s home, resulting in limited adherence. 
In order to improve patients’ adherence, we chose a one session-per-week formula 
under the supervision of a physician in a short time period (12 weeks). We obtained 
100% of adherence with this scheme. Importantly, all patients were very motivated to 
participate to the program suggesting the importance of a good motivational pre-
intervention counselling. Although in a small group of 3 patients, with no power to detect 
statistically significant differences, we hereby describe an improvement in HAND 
through a new computer-based tool of cognitive rehabilitation in the setting of treated 
HIV infection. In particular, we show an improvement in the executive functioning, atten-
tion/working memory, memory and motor skills. Future research with larger samples 
should be performed to evaluate the efficacy of our restorative computer-based program 
in improving other cognitive domains. Moreover, we observed an improvement in daily 
life activities, with a better quality of life and a reduction of anxiety symptoms. This 
outcome suggests that improving cognitive functions could result in a better emotional 
wellbeing and that a frequent interaction between patients and physician can reduce 
psychological apprehension of people living with HIV. 
Our experience supports the need to explore innovative ways to manage HAND in HIV-
infected patients. A study with a large cohort should be designed to assess the real 
effectiveness and feasibility of a computer-based neurocognitive approach in the 
management of this HIV-related comorbidity. Furthermore, a short and long-term follow-
up will be necessary to determine the durability of the rehabilitation program’s outcome. 
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Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV-associated neurocognitive disorders still need to be evaluated in the clinical 
management of both untreated and treated HIV-positive patients, given their relatively 
high prevalence. We have reported cognitive impairment in symptomatic HIV-positive 
patients on active treatment that display a long history of HIV infection with a low CD4+ 
nadir. Moreover, in our cohort, also asymptomatic naive patients, with a short time since 
first HIV diagnosis and with median CD4+ T cells higher than 200 cells/mmc could 
display cognitive impairment. We confirm that nowadays the majority of these cognitive 
disorders are asymptomatic or mild forms, while dementia is now a rare finding. 
However, the definition of a universally validated screening test is still a matter of 
debate; the “Three Questions test”, proposed as first approach for cognitive deficits by 
EACS guidelines, showed a low performance both in antiretroviral-naïve and on cART 
patients in our cohort. These data confirm the lack of association between subjective, 
self-reported cognitive symptoms and the objective measure of cognitive impairment 
and suggest the need of a new, easy-to-perform and quick test for the screening of 
HAND. 
Both traditional and new risk factors for HAND have been identified: besides the well 
recognized factors such as severe immune depression, long length of HIV infection and 
detectable plasma HIV-RNA, also social parameters, as well as foreign origin and 
unemployment, and non infectious comorbidities could participate in the development of 
HIV-associated cognitive disorders. Therefore, early diagnosis and prompt treatment of 
HIV infection thanks to screening services, programs aimed to improve retention in care 
and cART adherence and a proper management of non infectious comorbidities are 
required to reduce the prevalence of HAND, especially in high risk groups of patients. 
Minor forms of HAND are also associated with a skewing of peripheral T-cell subsets 
and an increased CSF to plasma HIV-RNA ratio in naive HIV-positive patients; 
furthermore, subjects with increased CSF/plasma ratio fail to reduce CNS pro-
inflammatory milieu under effective antiretroviral treatment. 
Before the introduction of antiretroviral treatment, the measurement of CSF viral load 
and the assessment of the CSF/plasma ratio could be useful in identifying subjects at 
high risk of developing HAND. In fact, these subjects could probably benefit from an 
antiretroviral treatment with an adequate CNS penetration and possibly cART 
complementary treatments. However, lumbar puncture is an invasive procedure and it is 
associated with possible complications. This consideration suggests the need for other 
non-invasive peripheral biomarkers.  
Most of the patients with HAND did not show any improvement in their cognitive 
function even after the introduction of virally suppressive cART, confirming that 
antiretroviral treatment alone is not enough to determine a complete resolution of these 
disorders.  
The lack of improvement despite suppressive cART is also seen in peripheral and 
central T cells phenotypes that maintain a pro-inflammatory pattern in subjects with high 
CSF to plasma HIV-RNA ratio. All these data underline the need of a closer follow-up of 
these patients and again support the possible benefit of early treatment to reduce 
neuroinflammation. 
An attempt to restore cognitive function in these patients could be a computer-base 
program of neurorehabilitation: the first results of this approach seem encouraging, 
even though the stability over time has to be yet demonstrated and larger randomized 
controlled trials are needed. 
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Figure 1 
Mechanisms of the HIV entry in the Central Nervous System 
 
 
 
 
LEGEND 
The proposed mechanisms of the HIV entry in the CNS. 1a) The Trojan horse mechanism, 1b) entry of 
cell-free viral particles, 1c) migration of HIV infected monocytes, leukocytes or perivascular 
macrophages.  
2) CNS resident cells that are susceptible of HIV infection: microglia, astrocytes, oligodendrocytes and 
neurons.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
Patogenetic mechanisms of neuro-inflammation 
 
 
LEGEND 
The proposed mechanisms of neuro-inflammation leading to neuronal injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
Algorithm for Diagnosis and Management of HIV-Associated Neurocognitive Impairment 
(NCI) in persons without obvious confounding conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EACS- European AIDS Clinical Society Guidelines – Version 9, October 2017 
 
 
Figure 4 
Neurocognitive domains and neuropsychological tests for the diagnosis of HAND 
 
 
Neuropsychological test Cognitive domains 
1)Forward and Backward Digit span Attention/working memory 
2)Corsi’s block Tapping Test 
3)Trail Making Test Part A-B (TMT A-B) 
4)Trail Making Test Part A (TMT A) Speed of information processing 
5) Stroop Color Test–Time 
6)Symbol Digit Modality Test 
7) Rey Auditory Verbal Learning Test 
Immediate Recall 
Learning and memory 
8)Rey Auditory Verbal Learning Test 
Delayed Recall 
9)Rey Osterrieth complex Delayed Recall 
10)Rey Osterrieth complex Figure Copy Abstraction/executive function 
11)Trail Making Test Part B (TMT-B) 
12)Stroop Color Test–Errors 
13)Semantic and Phonemic Fluency Verbal fluency 
14) Finger Tapping Test Motor skills 
15)Instrumental Activities of Daily Living 
Questionnaire (IADL) 
Functional 
LEGEND 
Table shows the neuropsychological tests used in this study (first column) and the explored cognitive 
domains (second column). 
Figure 5 
Most common biomarkers for HAND (by Blokhuis C et al, Dove Press 2016; 7:1-13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 
The CPE score (by Letendre S et al, Arch Neurol 2008; 65 (1):65-70). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 
Algorithm for the management of HAND in HIV-positive patients on stable cART (proposed by 
Underwood J and Winston A, Curr HIV/AIDS Res 2016; 13:235-240). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 
Algorithm for the management of HAND in HIV-positive patients on stable cART (proposed by 
Calcagno A et al, Drugs 2017; 77:145-157). 
 
 
 
 
 
Table 1 
Characteristics of study population 
 
Characteristics 
Population 
(N 302) 
Antiretroviral 
naïve patients  
(N 191) 
On cART 
patients 
(N 111) 
p value 
Demographic parameters     
Age, years* 44 (35-51) 40 (32-48) 49 (42-55) 0,0001 
Males° 244 (81%) 167 (87%) 77 (69%) 0,0001 
Months since HIV diagnosis* 16 (1-119) 2 (1-14) 208 (84-322) 0,0001 
Risk factor for HIV° 
MSM 
Heterosexuals 
IDUs 
 
180 (60%) 
110 (36%) 
12 (4%) 
 
140 (74%) 
43 (22%) 
8 (4%) 
 
40 (36%) 
67 (60%) 
4 (4%) 
0,0001 
HCV coinfection° 60 (20%) 14 (7%) 46 (41%) 0,0001 
HBV coinfection° 7 (2%) 3 (1.5%) 4 (4%) 0,263 
AIDS diseases° 52 (17%) 28 (15%) 24 (22%) 0,114 
cART regimen° 
PI 
NNRTI 
INSTI 
Other 
- - 
 
32 (29%) 
36 (32%) 
31 (28%) 
12 (11%) 
 
Comorbidities° 82 (27%) 41 (21%) 41 (37%) 0,004 
Unemployment° 35 (11%) 19 (10%) 16 (14%) 0,15 
Viro-immunological parameters     
CD4+ T cells nadir, cells/mmc* 311 (163-469) 368 (183-500) 259 (155-400) 0,002 
Current CD4+ T cells, 
cells/mmc* 
455 (277 (626) 399 (233-551) 567 (398-760) 0,0001 
Current CD4/CD8 ratio* 0,55 (0,32-0,8) 0,37 (0,22-0,64) 0,69 (0,44-0,94) 0,0001 
Log10 HIVRNA cp/mL* 4,62 (4,01-5,29) 4,64 (4,08-5,3) 3,7 (1,67-5) 0,0034 
Undetectable HIVRNA° - - 94 (85%)  
Neuropsychological parameters     
Altered SF-36 MHI° 121 (40%) 82 (43%) 39 (35%) 0,243 
Altered SF-36 PHI° 52 (17%) 30 (16%) 22 (20%) 0,299 
Altered HADS depression° 38 (12%) 47 (25%) 45 (40%) 0,004 
Altered HADS anxiety° 92 (30%) 18 (9%) 20 (18%) 0,03 
A3QT° 99 (33%) 45 (23%) 54 (49%) 0,0001 
HAND° 
ANI 
MND 
HAD 
82 (27%) 
71 (86%) 
10 (12%) 
1 (2%) 
43 (22%) 
39 (90%) 
3 (7%) 
1 (3%) 
39 (35%) 
32 (82%) 
7 (18%) 
0 
0,017 
LEGEND 
MSM, Men who have sex with men; IDUs, Intravenous Drug Users; cART, combination antiretroviral 
therapy; PI, Protease Inhibitors, NNRTI, Non Nucleoside Reverse Transcriptase Inhibitors, INSTI, 
Integrase Inhibitors, Other, other regimens (monotherapies or dual therapies). Comorbidities, GFR <90 
ml/min, cardiovascular diseases, cancers. SF-36 MHI, Mental Health Index by SF-36 survey; SF-36 PHI, 
Physical Health Index by SF-36 survey. 
HADS, Hospital Anxiety and Depression Scale, score >11 was considered pathological. 
*Data are presented as Median (Interquartile Range), p values by Mann Whitney test. 
°Data are presented as absolute numbers (percentages), p values by Chi-squared test. 
Figure 9 
Proportion of “abnormal” 3QT (a) and HAND (b) in the study population 
 
  
 
 
 
 
 
LEGEND 
a3QT, patients with “abnormal” 3QT; n3QT, patients with normal 3QT. 
HAND, HIV-Associated neurocognitive Disorders; ANI, Asymptomatic Neurocognitive 
Impairment, MND, Mild Neurocognitive Disorders, HAD, HIV-Associated Dementia. 
a) Proportion of patients with a3QT and n3QT 
b) Proportion of patients with forms of HAND and of patients without neurocognitive impairment 
c) Proportion of HAND cases in patients with a3QT and n3QT 
 
 
 
 
 
33% 
67% 
3QT results 
a3QT 
n3QT 
a) 
23.5% 
3.7% 
0.3% 
72.5% 
HAND diagnosis 
ANI 
MND 
HAD 
normal 
b) 
a3QT n3QT 
35 pts, 
 35% 
47 pts,  
24% 
64 pts,  
65% 
156 pts, 
 76% 
HAND noHAND c) 
Table 2 
Sensitivity, specificity, negative and positive predictive value of 3QT. 
 
Statistical Parameters Population (N 302) 
Antiretroviral naive 
patients (N 191) 
On cART  
patients (N 111) 
Sensitivity 43 (32-53) 30 (16-44) 56 (41-72) 
Specificity 71 (65-77) 78 (72-85) 44 (33-56) 
Positive Predictive Value 35 (26-45) 29 (25-33) 38 (26-51) 
Negative Predictive Value 77 (71-83) 79 (73-85) 70 (58-82) 
 
LEGEND 
Data are presented with 95% Confidence Interval.  
Sensitivity is the probability that a test will indicate 'disease' among those with the disease, Specificity is 
the fraction of those without disease who will have a negative test result. Positive predictive value is 
the probability that subjects with a positive screening test truly have the disease, while Negative 
predictive value is the probability that subjects with a negative screening test truly don't have the 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 
Receiver operating characteristic curve, 3 Questions Test. 
 
a  
 
 
 
LEGEND 
Receiver operating characteristic curve, ROC curve, for the “3 Questions test”. Participants with HAND 
versus those without cognitive impairment. Area under the curve=0,568, 95%CI 0,494-0,642. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 
Receiver operating characteristic curve, 3 Questions Test in antiretroviral naïve and on 
treatment HIV-positive patients. 
a) 
 
b) 
 
 
LEGEND 
Receiver operating characteristic curve, ROC curve, for the “3 Questions test”: a) antiretroviral naïve 
patients, Area under the curve=0,56, 95%CI 0,448-0,672. b) treated patients, Area under the 
curve=0,543, 95%CI 0,443-0,643. Participants with HAND versus those without cognitive impairment.  
Table 3 
Factors associated with “abnormal” 3QT by fitting an univariable and multivariable logistic 
regression model 
 
Characteristics Crude OR (95% CI) p value Adjusted OR (95% CI) p value 
Age,  each year more 1,019 (0,997-1,042) 0,087 0,999 (0,97-1,03) 0,209 
Males 
Females 
Ref 
2,717 (1,513-4,88) 
 
0,001 
Ref 
1,718 (0,739-3,993) 
 
0,957 
Months since HIV 
diagnosis,  
each month more 
1,003 (1,001-1,005) 0,004 0,999 (0,995-1,002) 
 
0,518 
Risk factor for HIV° 
Heterosexuals 
MSM 
IDUs 
 
Ref 
0,514 (0,31-0,852) 
1,444 (0,438-4,766) 
 
0,026 
0,01 
0,546 
 
Ref 
0,936 (0,421-2,081) 
1,04 (0,185-5,833) 
 
0,983 
0,871 
0,965 
Hepatitis coinfection 
(yes vs no) 
1,304 (0,734-2,318) 0,366   
AIDS diseases 
(yes vs no) 
1,513 (0,818-2,801) 0,187   
On cART patients 
Antiretroviral naïve 
patients 
Ref 
0,325 (0,197-0,537) 
 
<0,0001 
Ref 
0,249 (0,103-0,602) 
 
0,002 
Comorbidities 
(yes vs no) 
1,61 (0,949-2,733) 0,078 1,374 (0,708-2,666) 0,348 
Unemployment 
(yes vs no) 
1,584 (0,771-3,256) 0,211   
CD4+ T cells nadir, each 
cells/mmc higher 
1 (0,998-1,001) 0,405   
Current CD4+ T cells, 
each cells/mmc higher 
1 (1-1,001) 0,361   
Current CD4/CD8 ratio, 
Each unit higher 
0,967 (0,431-2,167) 0,935   
Log10 HIVRNA cp/mL, 
Each log10 cp/mL higher 
0,893 (0,628-1,269) 0,527   
Altered SF-36 MHI, 
(yes vs no) 
2,4 (1,438-4,005) 0,001 2,86 (1,427-5,73) 0,003 
Altered SF-36 PHI, 
(yes vs no) 
3,124 (1,683-5,797) <0,0001 4,073 (1,879-8,828) <0,0001 
Altered HADS 
depression, 
(yes vs no) 
2,114 (1,261-3,545) 0,005 0,504 (0,181-1,406) 0,191 
Altered HADS anxiety, 
(yes vs no) 
2,593 (1,298-5,178) 0,007 0,802 (0,386-1,6659 0,533 
HAND, (yes vs no) 1,815 (1,073-3,07) 0,026 1,216 (0,629-2,352) 0,56 
 
LEGEND 
OR, odds ratio; 95% CI, 95% confidence interval. 
MSM, Men who have sex with men; IDUs, Intravenous Drug Users; cART, combination antiretroviral 
therapy; Comorbidities, GFR <90 ml/min, cardiovascular diseases, cancers. SF-36 MHI, Mental Health 
Index by SF-36 survey; SF-36 PHI, Physical Health Index by SF-36 survey. HADS, Hospital Anxiety and 
Depression Scale, score >11 was considered pathological. Multivariable analysis included the following 
variables: age, gender, months since HIV diagnosis, risk factor for HIV, being antiretroviral naïve, 
comorbidities, altered HADS depression and anxiety score, altered SF-36 MHI and PHI score and HAND.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 
Factors associated with “abnormal” 3QT by fitting an univariable and multivariable logistic 
regression model in untreated HIV-infected patients 
 
Characteristics Crude OR (95% CI) p value Adjusted OR (95% CI) p value 
Age,  each year more 0,994 (0,9963-1,026) 0,691   
Males 
Females 
Ref 
2,694 (1,103-6,579) 
 
0,03 
Ref 
1,765 (0,665-4,683) 
0,254 
Months since HIV 
diagnosis,  
each month more 
1,003 (0,998-1,009) 0,277   
Risk factor for HIV° 
Heterosexuals 
MSM 
IDUs 
 
Ref 
0,518 (0,242-1,108) 
1,243 (0,259-5,956) 
 
0,158 
0,09 
0,786 
  
Hepatitis coinfection 
(yes vs no) 
0,998 (0,309-3,229) 0,997   
AIDS diseases 
(yes vs no) 
1,362 (0,555-3,344) 0,5   
Comorbidities 
(yes vs no) 
1,082 (0,482-2,429) 0,849   
Unemployment 
(yes vs no) 
1,163 (0,394-3,433) 0,785   
CD4+ T cells nadir, each 
cells/mmc higher 
1 (0,998-1,001) 0,589   
Current CD4+ T cells, 
each cells/mmc higher 
1 (0,999-1,001) 0,987   
Current CD4/CD8 ratio, 
Each unit higher 
0,599 (0,121-2,962) 0,53   
Log10 HIVRNA cp/mL, 
Each log10 cp/mL higher 
1,025 (0,681-1,542) 0,907   
Altered SF-36 MHI, 
(yes vs no) 
2,684 (1,309-5,501) 0,007 2,309 (1,104-4,83) 0,026 
Altered SF-36 PHI, 
(yes vs no) 
2,644 (1,15-6,083) 0,022 2,056 (0,855-4,941) 0,017 
Altered HADS 
depression, 
(yes vs no) 
1,658 (0,583-4,714) 0,343   
Altered HADS anxiety, 
(yes vs no) 
1,283 (0,603-2,728) 0,518   
HAND, (yes vs no) 1,571 (0,735-3,357) 0,244 1,277 (0,552-2,953) 0,567 
 
LEGEND 
OR, odds ratio; 95% CI, 95% confidence interval. 
MSM, Men who have sex with men; IDUs, Intravenous Drug Users; Comorbidities, GFR <90 ml/min, 
cardiovascular diseases, cancers. SF-36 MHI, Mental Health Index by SF-36 survey; SF-36 PHI, Physical 
Health Index by SF-36 survey. HADS, Hospital Anxiety and Depression Scale, score >11 was considered 
pathological. Multivariable analysis included the following variables: gender, altered SF-36 MHI and PHI 
score and HAND.  
 
 
Table 5 
Factors associated with “abnormal” 3QT by fitting an univariable and multivariable logistic 
regression model in treated HIV-infected patients 
 
Characteristics Crude OR (95% CI) p value Adjusted OR (95% CI) p value 
Age,  each year more 1,014 (0,975-1,054) 0,495   
Males 
Females 
Ref 
1,807 (0,797-4,093) 
 
0,156 
  
Months since HIV 
diagnosis,  
each month more 
0,999 (0,995-1,002) 0,415   
Risk factor for HIV° 
Heterosexuals 
MSM 
IDUs 
 
Ref 
1,103 (0,5-2,432) 
3,484 (0,345-35,223) 
 
0,568 
0,808 
0,29 
  
Hepatitis coinfection 
(yes vs no) 
0,654 (0,306-1,396) 0,272   
AIDS diseases 
(yes vs no) 
1,359 (0,548-3,369) 0,508   
Comorbidities 
(yes vs no) 
1,661 (0,762-3,62) 0,202   
Unemployment 
(yes vs no) 
1,707 (0,568-5,128) 0,34   
CD4+ T cells nadir, each 
cells/mmc higher 
1,001 (0,999-1,003) 0,476   
Current CD4+ T cells, 
each cells/mmc higher 
0,999 (0,998-1,001) 0,438   
Current CD4/CD8 ratio, 
Each unit higher 
0,461 (0,149-1,429) 0,18   
HIVRNA < 40 c/mL 
(yes vs no) 
1,623 (0,57-4,627) 0,365   
Altered SF-36 MHI, 
(yes vs no) 
3,028 (1,317-6,964) 0,009 2,827 (0,899-8,89) 0,075 
Altered SF-36 PHI, 
(yes vs no) 
3,917 (1,384-11,084) 0,01 3,613 (1,519-11,263) 0,027 
Altered HADS 
depression, 
(yes vs no) 
3,09 (1,084-8,807) 0,035 0,707 (0,167-2,981) 0,636 
Altered HADS anxiety, 
(yes vs no) 
2,721 (1,229-6,023) 0,014 1,314 (0,475-3,63) 0,599 
HAND, (yes vs no) 1,618 (0,738-3,548) 0,23 1,6125 (0,631-4,183) 0,314 
 
LEGEND 
OR, odds ratio; 95% CI, 95% confidence interval. 
MSM, Men who have sex with men; IDUs, Intravenous Drug Users; Comorbidities, GFR <90 ml/min, 
cardiovascular diseases, cancers. SF-36 MHI, Mental Health Index by SF-36 survey; SF-36 PHI, Physical 
Health Index by SF-36 survey. HADS, Hospital Anxiety and Depression Scale, score >11 was considered 
pathological. Multivariable analysis included the following variables: altered HADS depression and 
anxiety score, altered SF-36 MHI and PHI score and HAND.  
 
 
Table 6 
Baseline characteristics of the study population. 
 
Characteristics  Untreated HIV+ patients 
(N 237) 
Treated HIV+ patients 
(N 116) 
Age, years, median, IQR *  39 (32-47) 50 (43-56) 
Males, n (%) ° 211 (89%) 81 (70%) 
Months since HIV diagnosis, median, IQR * 2 (1-13) 200 (81-311) 
Hepatitis coinfection, n (%) ° 23 (10%) 50 (43%) 
Risk factor for HIV, n (%)° 
MSM 
Heterosexuals 
IDUs  
 
173 (73%) 
55 (23%) 
9 (4%) 
 
41 (35%) 
68 (59%) 
7 (6%) 
Not Italian, n (%) ° 24 (10%) 4 (4%) 
AIDS events, n (%) ° 42 (18%) 29 (25%) 
CD4+ T-cells nadir, cells/mmc, median, IQR * 368 (220-526) 252 (150-399) 
CD4/CD8 ratio, median, IQR * 0,37 (0,22-0,64) 0,68 (0,44-0,94) 
Plasma Log10 HIV-RNA, cp/mL, median, IQR * 4,71 (4,09-5,34) 3,26 (1,59-4,21) 
CSF Log10 HIV-RNA, c/mL , median, IQR * 
(N of patients)  
3,64 (3,02-4,16) 
(N 189) 
4,22 (3,54-5,09) 
(N 39) 
Plasma HIV-RNA >50 cp/mL, n (%) ° - 27 (23%) 
CSF HIV-RNA >50 cp/mL, n (%) ° - 13/39 (33%) 
Viral Escape, n (%) ° - 7/39 (18,4%) 
cART regimen, n (%) ° 
PI-based  
NNRTI-based  
INSTI-based  
Dual therapies  
- 
 
34 (29%) 
36 (31%) 
33 (28%) 
13 (12%) 
CPE score, median, IQR * - 7 (6-8) 
Years of education, median, IQR * 13 (8-17) 8 (8-13) 
Unemployed pts, n (%) ° 19 (8%) 16 (14%) 
Comorbidities, n (%) ° 41 (17%) 41 (35%) 
 
LEGEND 
HAND, HIV-Associated Neurocognitive Disorders; MSM, Men who have sex with men; IDUs, Intravenous 
Drug Users; Pts, patients; CSF, Cerebrospinal fluid; cp/mL, copies/mL; cART, combination antiretroviral 
therapy. Comorbidities: GFR <90 ml/min, Framingham risk score >20%, cancers. 
*Data are presented as Median (Interquartile Range) - °Data are presented as absolute numbers 
(percentages). 
Figure 12 
Prevalence of HAND in untreated and cART-treated patients. 
 
 
LEGEND 
Proportion of patients with normal neurocognitive performance and HAND in antiretroviral-naïve and 
cART-treated patients.  
HAD, HIV-Associated Dementia; MND, Mild Neuocognitive Disorders; ANI, Asymptomatic 
Neurocognitive Impairment. 
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Table 7 
Factors associated with HAND in antiretroviral-naïve HIV-infected patients by fitting an 
univariate and multivariate logistic regression model. 
 
Parameters  Univariate Multivariate 
 
OR (95% CI) 
p 
values 
AOR (95% CI) p values 
Age, each year more  1,02 (0,99-1,05) 0,145 1,002 (0,959-1,047) 0,927 
Females 
Males 
1 
0,523 (0,224-1,224) 
0,135   
Months since HIV diagnosis,  
each month more  
1,001 (0,996-1,006) 0,752 1,002 (0,994-1,01) 0,602 
AIDS events  
No 
Yes  
 
1 
3,756 (1,873-7,534) 
0,0001  
1 
1,958 (0,606-6,328) 
0,262 
Hepatitis coinfection  
No 
Yes  
 
1 
1,58 (0,635-3,933) 
0,325  
1 
1,022 (0,257-4,06) 
0,975 
Italian nationality  
Not Italian nationality  
1 
4,567 (1,871-11,15) 
0,001 1 
7,27 (2,535-20,873) 
0,0001 
Normal SF-36 physical health score 
Impaired SF-36 physical health score  
1 
2,502 (1,071-5,846) 
0,034   
Normal SF-36 mental health score 
Impaired SF-36 mental health score  
1 
1,511 (0,741-3,082) 
0,256   
Normal HADS-A  
Impaired HADS-A  
1 
1,117 (0,507-2,462) 
0,784   
Normal HADS-D  
Impaired HADS-D  
1 
1,418 (0,473-4,246) 
0,533   
Education  
Each year more 
 
0,904 (0,822-0,993) 
0,036 0,938 (0,832-1,058) 0,296 
Comorbidities  
No 
Yes  
 
1 
0,951 (0,414-2,187) 
0,906  
1 
0,748 (0,283-1,973) 
0,557 
Employed patients  
Unemployed patients  
1 
5,801 (2,158-15,59) 
0,0001 1 
4,103 (1,27-13,248) 
0,018 
CD4+ T-cells nadir,  
each cell/mmc more  
0,996 (0,995-0,999)  0,0001  0,998 (0,995-0,999)  0,044 
Log10 HIV-RNA copies/mL 
each copies/mL more 
0,939 (0,675-1,305) 0,708   
 
LEGEND 
Univariable and multivariable logistic regression analysis. OR, odds ratio; 95% CI, 95% confidence 
interval. AOR, adjusted odds ratio. Comorbidities: GFR <90 ml/min, Framingham risk score >20%, 
cancers. SF-36 MHI, Mental Health Index by SF-36 survey; SF-36 PHI, Physical Health Index by SF-36 
survey. HADS, Hospital Anxiety and Depression Scale, score >11 was considered pathological. 
Multivariable analysis included the following variables: AIDS diseases, CD4+ T cells nadir, age, months 
since HIV diagnosis, hepatitis coinfection, years of education, comorbidities, nationality and 
employment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8 Factors associated with HAND in cART-treated HIV-infected patients by fitting an 
univariate and multivariate logistic regression model. 
 
Parameters  Crude OR (95%CI) p values AOR (95%CI) p values 
Age, each year more  0,995 (0,957-1,034) 0,78 0,944 (0,888-1,003) 0,063 
Females 
Males 
1 
0,627 (0,28-1,407) 
0,258   
Months since HIV diagnosis,   
each month more  
1,0 (0,999-1,006) 0,119 1,006 (1-1,013) 0,05 
AIDS events 
No 
Yes  
 
1 
3,756 (1,873-7,534) 
0,0001  
1 
0,5019 (0,081-3,121) 
0,459 
Hepatitis coinfection 
No 
Yes  
 
1 
1,57 (0,737-3,352) 
0,242  
1 
1,151 (0,279-4,747) 
0,846 
Italian nationality  
Not Italian nationality  
1 
1,892 (0,256-13,98) 
0,532   
Normal SF-36 physical health 
score 
Impaired SF-36 physical health 
score  
1 
1,686 (0,633-4,486) 
0,296   
Normal SF-36 mental health score 
Impaired SF-36 mental health 
score  
1 
1,132 (0,48-2,667) 
0,777   
Education 
Each year more 
0,962 (0,872-1,062) 0,446 0,862 (0,729-1,019) 0,082 
Comorbidities  
No 
Yes  
 
1 
2,273 (1,01-5,108) 
0,047  
1 
4,757 (0,916-9,612) 
0,07 
Normal HADS-A  
Impaired HADS-A  
1 
1,131 (0,502-2,546) 
0,766   
Normal HADS-D  
Impaired HADS-D  
1 
3,875 (1,41-10,65) 
0,009 1 
5,221 (1,095-24,885) 
0,038 
Employment patients  
Unemployed patients  
1 
4,823 (1,52-15,3) 
0,008 1 
2,898(0,527-15,938) 
0,221 
CD4+ T-cells nadir,  
each cell/mmc more  
1 (0,998-1,003) 0,755 1,004 (0,999-1,008) 0,092 
Log10 HIV-RNA copies/mL 
each copies/mL more 
0,939 (0,675-1,305) 0,708   
Plasma HIV-RNA >50 c/mL 
No 
Yes  
 
1 
4,125 (1,419-11,991) 
0,009  
1 
16,28 (2,225-117,64) 
0,006 
CPE score, each score more  0,397 (0,115-1,379) 0,146   
Months of cART treatment,  
each month more  
1 (1-1,001) 0,213   
cART  
3 drugs  
Mono-dual therapies  
 
1 
2,926 (0,889-9,626) 
0,077   
LEGEND 
Univariable and multivariable logistic regression analysis. OR, odds ratio; 95% CI, 95% confidence 
interval. AOR, adjusted odds ratio. Comorbidities: GFR <90 ml/min, Framingham risk score >20%, 
cancers. SF-36 MHI, Mental Health Index by SF-36 survey; SF-36 PHI, Physical Health Index by SF-36 
survey. HADS, Hospital Anxiety and Depression Scale, score >11 was considered pathological. 
Multivariable analysis included the following variables: AIDS diseases, CD4+ T cells nadir, proportion of 
patients with detectable HIV-RNA, age, months since HIV diagnosis, education, hepatitis, comorbidities, 
symptoms of depression and employment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9 
Comparison between subjects with normal neurocognitive function and patients with 
neurocognitive impairment 
 
Total population n=189 No HAND  
(n=136) 
HAND  
(n= 53) 
p value 
Demographic characteristics 
Female, n (%) *  10 (7.4) 8 (15.)1 0.164 
Age (years), median (IQR)°  38 (30-45) 39 (33-48) 0.105 
Time since first HIV diagnosis (months),  
median  (IQR)°  
2 (1-12) 2 (0.5-24) 0.295 
AIDS events, n (%)* 18 (13.2) 21 (40) 0.0001 
Risk factor for HIV, n (%) 
Heterosexuals 
MSM 
Ex IDUs 
 
25 (18.4%) 
104 (76.5%) 
7 (5.1%) 
 
14 (20.6%) 
37 (69.8%) 
2 (3.8%) 
0.456 
HCV Ab positive, n (%) 9 (6.6%) 4 (7.5%) 0.76 
HBsAg positive, n (%) 4 (2.9%) 2 (3.8%) 0.674 
Viro-immunological parameters 
Plasma HIV-RNA, Log10 cp/ml median (IQR)°  4.63 (4.09-5.39) 4.79 (4.21 -5.3) 0.806 
CSF HIV-RNA, Log10 cp/ml median (IQR)°  3.61 (3-4.11) 3.67 (3.19-4.4) 0.839 
CSF to plasma HIV-RNA ratio, median (IQR)° 0.76 (0.61-0.86) 0.79 (0.62-1.01) 0.371 
Pts with CSF to plasma HIV-RNA ratio ≥1, n (%)* 15 (11.3) 15 (28.3) 0.004 
Nadir CD4+ T-cells, cell/mmc median (IQR)° 381 (249-492) 274 (74-411) 0.0001 
Pts with nadir CD4+ T-cells <200 cell/mmc, n (%)* 34 (25.4) 26 (52) 0.001 
CD8+% T-cells,  median (IQR)° 56 (48-65) 59 (49-70) 0.005 
CD4/CD8 ratio, median (IQR)°  0.38 (0.21-0.5) 0.3 (0.15-0.47) 0.455 
T cell activation 
CD38+CD8+%, median (IQR)°  12 (7-20) 12 (8-20) 0.094 
CD45R0+CD38+CD8+%, median (IQR)°  7 (4-15) 8 (4-15) 0.059 
T cell maturation/differentiation 
CD127+CD4+%, median (IQR)°  13 (8-17) 10 (5-14) 0.001 
CD127+CD8+%, median (IQR)°  29 (24-37) 28 (23-37) 0.182 
CD45RA+CD4+%, median (IQR)°  8 (5-12) 6 (2-9) 0.0001 
CD45RA+CD8+%, median (IQR)°  19 (13-24) 18 (14-25) 0.777 
CD45R0+CD8+%, median (IQR)°  23 (17-31) 21 (16-33) 0.055 
 
LEGEND 
HAND, HIV-Associated Neurocognitive Disorders; MSM, Men who have sex with men; IDUs, Intravenous 
Drug Users; Pts, patients; CSF, Cerebrospinal fluid; cp/mL, copies/mL. 
CSF to plasma HIV-RNA ratio was calculated as log10 CSF HIV-RNA divided by log10 plasma HIV-RNA 
copies/mL. 
*Data are presented as Median (Interquartile Range), p values by Mann Whitney test. 
°Data are presented as absolute numbers (percentages), p values by Chi-squared test or Fisher exact 
test as appropriate. 
 
 
 
 
 
Table 10 
Factors independently associated with HIV-Associated Neurocognitive Disorders (HAND) by 
fitting a multivariable logistic regression analysis. 
 
Total population n=189 Multivariate analysis 
 AOR 95%CI p value 
AIDS 
No 
Yes 
 
Ref 
3.441 
 
 
1.38-8.58 
 
 
0.008 
Pts with CSF to plasma HIV-RNA ratio <1 
Pts with CSF to plasma HIV-RNA ratio ≥1 
Ref 
2.707 
 
1.122-6.531 
 
0.027 
Nadir CD4+ T-cells ≥200 cells/mmc 
Nadir CD4+ T-cells <200 cells/mms 
Ref 
1.803 
 
0.8-4.06 
 
0.155 
 
LEGEND 
AOR, adjusted odds ratio; 95% CI, 95% confidence interval. Each variable is mutually adjusted. 
Pts, patients; CSF to plasma HIV-RNA ratio was calculated as log10 CSF HIV-RNA divided by log10 plasma 
HIV-RNA copies/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  
Diagram illustrating patients’ assignments to peripheral blood (PB) and CSF analyses and to 
neurocognitive screening test. 
 
Figure 1. Cohort diagram illustrating the study population
 
 
 
LEGEND 
Seventy HIV-infected cART naïve subjects were enrolled and assigned to underwent blood and CSF 
collection. Thirty-three patients underwent lumbar puncture and blood withdrawal at T12 as well. 
Twenty-two patients agreed to performed a short screening neurocognitive battery, consisting of Mini 
Mental State Examination (MMSE), Frontal Assessment Battery (FAB) and International HIV Dementia 
Scale (IHDS) both at T0 and T12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11 
Baseline demographic and viro-immunological features of the study population. 
 
 Total 
(n=70) 
L-CSF 
(n=61) 
H-CSF 
(n=9) 
p values 
Females, yes (%)* 5 (7) 4 (6.5) 1 (11) 0.508 
Age, years, (IQR)° 39 (32-46) 38 (31-45) 39 (37-55) 0.136 
HCV co-infection, yes (%)* 3 (4) 3 (5) 0 1 
HBV co-infection, yes (%)* 3 (4) 3 (5) 0 1 
CMV IgG levels, (IQR)° 102 (36-141) 101 (42-139) 131 (22-180) 0.755 
Mode of HIV transmission, (%)*    0.188 
Homo/Bisexual contact 47 (67) 43 (70) 4 (45)  
Heterosexual contact 7 (10) 11 (18) 4 (45)  
IDU/Other 16 (23) 7 (12) 1 (10)  
Time since 1st HIV diagnosis, months 
(IQR)° 
2.5 (1-8) 2 (1-8.5) 3 (1.5-6) 0.978 
AIDS-defining conditions, yes (%)* 12 (17) 10 (16) 2 (22) 0.646 
Plasma HIV-RNA, Log cp/ml (IQR)° 5,06 (4,22-5,62) 5,07 (4,51-5,64) 4,04 (2,59-4,90) 0.009 
CSF HIV-RNA, Log cp/ml (IQR)° 3,57 (2,92-4,06) 3,52 (2,91-3,87) 4,42 (3,04-5,72) 0.034 
Total plasma HIV-DNA, 
 cp/10*6 PBMC, (IQR)° 
987 (205-2380) 1480 (246-3226) 189 (93-556) 0.064 
CD4 T-cell count, mmc/ml (IQR)°     
Nadir CD4 166 (38-340) 179 (32-347) 123 (39-309) 0.0667 
At time of analyses 326 (218-416) 339 (242-438) 183 (123-326) 0.050 
CD8 T-cell count, mmc/ml (IQR)° 992 (785-1197) 996 (715-1184) 895 (841-1756) 0.695 
CD4/CD8 ratio, (IQR)° 0,33 (0,17-0,41) 0,35 (0,20-0,47) 0,14 (0,10-0,36) 0.026 
 
LEGEND 
°Data are median (IQR). Statistical analyses: Mann-Whitney U Test. *Data are n (%). Statistical analyses: 
Pearson Chi squared or Fisher Exact Test. IQR: Interquartile range; CSF: cerebrospinal fluid; H-CSF: High 
cerebrospinal fluid (CSF/plasma HIV-RNA ≥1); L-CSF: Low cerebrospinal fluid (CSF/plasma HIV-RNA<1). 
IDU: intravenous drug users. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12 
Plasma Inflammation/Activation, Maturation and Cytokines Production. 
 
 
 
 Total 
(n=70) 
L-CSF 
(n=61) 
H-CSF 
(n=9) 
p 
values 
Peripheral blood markers 
T cell activation, median (IQR)     
CD8+38+, % 12,0 (9,00-20,30) 12,00 (9,00-20,00) 12,00 (5,00-32,00) 0.613 
CD8+CD38+CD45R0+, % 7,00 (5,00-13,30) 7,00 (5,00-13,00) 6,00 (4,00-16,00) 0.634 
HLA-DR+CD38+CD4+, % 2,10 (1,00-5,10) 1,90 (0,95-5,05) 3,30 (1,03-6,85) 0.522 
HLA-DR+CD38+CD8+, % 8,35 (4,50-14,50) 8,35 (4,45-13,73) 8,35 (5,58-18,55) 0.734 
T-cell proliferation, median (IQR)     
KI67+CD4+, % 3,10 (1,75-6,60) 3,15 (1,80-6,55) 1,90 (1,60-9,40) 0.579 
KI67+CD8+, % 2,90 (1,55-5,75) 2,95 (1,75-5,68) 2,00 (0,80-6,50) 0.386 
T-cell maturation, median (IQR)     
CD4+CCR7+CD45RA+ (naive), % 2,00 (1,05-3) 2,00 (1,20-3,10) 1,25 (0,28-4,20) 0.406 
CD4+CCR7+CD45RA- (CM), % 3,80 (2,40-5,10) 3,90 (2,43-5,43) 2,65 (2,35-4,70) 0.494 
CD4+CCR7-CD45RA+ (TD), % 36,9 (27,3-46,30) 36,80 (27,53-45,13) 42,30 (14,68-52,68) 0.692 
CD4+CCR7-CD45RA- (EM), % 56,3 (45,90-66,7) 56,30 (45,83-66,55) 51,75 (42,15-82,13) 0.885 
CD8+CCR7+CD45RA+ (naive), % 1,20 (0,70-2,40) 1,15 (0,70-2,45) 1,50 (0,80-2,40) 0.717 
CD8+CCR7+CD45RA- (CM), % 1,50 (1,00-2,10) 1,50 (1,03-2,08) 1,50 (0,80-2,10) 0.908 
CD8+CCR7-CD45RA+ (TD), % 42,10 (32,1-47,7) 43,40 (33,83-47,60) 32,10 (26,90-48,70) 0.172 
CD8+CCR7-CD45RA- (EM), % 54.10 (47-64,80) 53,95 (44,30-62,50) 64,90 (49,70-70,30) 0.126 
Plasma Cytokines, median (IQR)     
IL-6, pg/ml 2,30 (0,80-4,00) 1,82 (0,68-3,76) 3,50 (1,54-6,27) 0.086 
TNFa, pg/ml 1,30 (0,60-3,50) 1,33 (0,60-3,60) 1,49 (0,62-4,08) 0.921 
sCD14, ug/ml 3,50 (2,60-5,00) 3,53 (2,64-4,92) 3,86 (2,78-5,36) 0.544 
IFN-ỿ, pg/ml 59,1 (41,1-67,70) 52,14(39,72-66,02) 65,85 (57,42-88,58) 0.068 
HIV-specific T-cell Response,  
median (IQR) 
    
CD4+IL2+IFNỿ+, % 0 (0-0) 0 (0-0,075) 0 (0-0) 0.939 
CD4+IL2+IFNỿ-, % 0,8 (0,1-1,8) 0,9 (0,4-1,6) 0,75 (0,025-1,898) 0.815 
CD4+IL2-IFNỿ+, % 0 (0-0,5) 0,2 (0-0,5) 0 (0-0,575) 0.713 
CD8+IL2+IFNỿ+, % 0 (0-0,1) 0,1 (0-0,2) 0 (0-0,1) 0.099 
CD8+IL2-IFNỿ+, % 0 (0-0,1) 0,1 (0-0,4) 0 (0-0,113) 0.406 
CMV-specific T-cell Response,  
median (IQR) 
    
CD4+IL2+IFNỿ+, % 0 (0-0,1) 0 (0-0,15) 0 (0-0,1) 0.8 
CD4+IL2+IFNỿ-, % 0,9 (0,2-2,3) 2 (1,3-3,3) 0,66 (0,12-2,1) 0.065 
CD4+IL2-IFNỿ+, % 0,4 (0-0,7) 0,5 (0,08-0,85) 0,4 (0-0,73) 0.782 
CD8+IL2+IFNỿ+, % 0 (0-0,1) 0 (0-0,1) 0 (0-0,095) 0.907 
CD8+IL2-IFNỿ+, % 0 (0-0,3) 0,2 (0-0,8) 0 (0-0,235) 0.442 
LEGEND 
All data are median (IQR). Statistical analyses: Mann-Whitney U Test. IQR: Interquartile range; CSF: 
cerebrospinal fluid; H-CSF: High cerebrospinal fluid (CSF/plasma HIV-RNA ≥1); L-CSF: Low cerebrospinal 
fluid (CSF/plasma HIV-RNA<1). CM: central memory, EM: effector memory, TD: terminally differentiated 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13 
CSF soluble markers. 
 
 
LEGEND 
All data are median (IQR). Statistical analyses: Mann-Whitney U Test. IQR: Interquartile range; CSF: 
cerebrospinal fluid; H-CSF: High cerebrospinal fluid (CSF/plasma HIV-RNA ≥1); L-CSF: Low cerebrospinal 
fluid (CSF/plasma HIV-RNA<1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Total 
(n=70) 
L-CSF 
(n=61) 
H-CSF 
(n=9) 
p 
values 
CSF Soluble Markers   
CSF Cytokines, median (IQR)     
sCD14, ng/ml 147 (78-264) 144,2 (72,91-232) 670 (78,44-1195) 0,204 
IL6, pg/ml 0,59 (0,5-1,14) 0,68 (0,5-1,25) 1,07 (0,48-1,94) 0,57 
TNF-α, pg/ml 0,86 (0,78-0,94) 0,86 (0,76-0,94) 1,17 (0,78-2,16) 0,123 
MCP-1, ng/ml 0,77 (0,63-1,11) 0,79 (0,64-1,12) 1,22 (0,54-1,52) 0,539 
IP-10, ng/ml 1,16 (0,47-39,9) 1,33 (0,49-68,1 2,41 (1,34-26,34) 0,798 
Neopterin, ng/ml 1,1 (0,77-1,50) 1,13 (0,83-2,21) 0,8 (0,22-4,15) 0,499 
CSF S100 Beta Protein, pg/ml median (IQR) 241 (99-380) 203,5 (76,75-376,5) 293 (78,5-343) 0,939 
Figure 14 
Correlations between CSF/plasma HIV-RNA and peripheral and CNS markers of immune 
activation/inflammation. 
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Figure 2. Correlations between CSF/plasma HIV-RNA and immune-activation/inflammation
a) b) c)
d) e) f)
 
LEGEND 
We investigated whether activation/inflammation markers might sustain high CSF HIV-RNA in untreated 
HIV-infected subjects. a) Plasma HIV-RNA positively correlates with HLA-DR+CD38+CD8+ (r=0.50, 
p=.003). b) We observed a positive association between  CSF HIV-RNA and HLA-DR+CD38+CD8+ (r=0.35, 
p=.046). c) CSF HIV-RNA positively correlates with IL-6 (r=0.39, p=.004). d) CSF HIV-RNA positively 
correlates with MCP-1 (r=0.30, p=.0.31). e) CSF HIV-RNA positively correlates with IP-10 (r=0.31, p=.033). 
f) CSF HIV-RNA positively correlates with neopterin (r=0.35, p=.005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 
Circulating pro-inflammatory markers and T-cell activation in L-CSF and H-CSF following 12 
months of cART 
 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 L-CSF 
(N=24) 
H-CSF 
(N=9) 
 T0 T12 p values T0 T12 p values 
Plasma HIV-RNA, log10 
cp/mL, (IQR) 
4,81  
(4,15-5,47) 
1,59 
 (1,59-1,59) 
<0,0001 5,45 
(4,75-5,79) 
1,59 
(1,59-1,59) 
0,0002 
CSF HIV-RNA, cp/mL, 
(IQR) 
3,25  
(2,56-3,65) 
1,59 
 (1,59-1,59) 
<0,0001 4,74 
 (4,32-5,12) 
1,59 
(1,59-1,59) 
0,0002 
Total HIV-DNA, cp/106 
PBMC, (IQR) 
987 
(176-211) 
225 
(16-598) 
0,125 668 
(195-3718) 
891 
(290-1097) 
0,5 
CD4+ T-cells, 
cells/mmc (IQR) 
353 
(268-447) 
573 
 (390-713) 
<0,0001 168 
(123-326) 
497 
(293-612) 
0,016 
CD8+ T-cells, 
cells/mmc (IQR) 
991 
(769-1138) 
794 
 (647-1275) 
0,978 1069 
(841-1789) 
1176 
(815-1462) 
0,848 
CD4/CD8 ratio, (IQR) 0,37  
(0,25-0,47) 
0,75  
(0,48-0,92) 
0,001 0,14 
(0,1-0,27) 
0,4 
(0,28-0,51) 
0,007 
cART regimen, n (%) 
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LEGEND 
Data are presented as median (IQR). We defined HIV+ patients as (i) H-CSF: CSF/plasma HIV-RNA  ratio 
≥1 and (ii) L-CSF CSF/plasma<1. 
a) Table summarizing the modifications of viro-immunological markers following 12 months of cART in 
both H-CSF and L-CSF patients. b) HIV+ as whole significantly reduced plasma TNF-α (1.35 pg/ml [0.62-
3.52] vs 0.61 pg/ml [0.54-1.02]; p=.008). Only L-SCF group showed a reduction of circulating TNF-α (1.33 
pg/ml [0.6-3.6] vs 0.69 pg/ml [0.6-1.09], p=.048). c) At T12, no differences in plasma IL-6 levels were 
observed in the study populations. d-e) We failed to find any differences after cART introduction in 
circulating sCD14 and IFN-ỿ in HIV+ as a whole, as well as in H-CSF and L-CSF. f) At T12, HIV+ patients as 
a whole significantly reduced activated CD38+CD8+ (p<.0001). Similarly, both H-CSF and L-CSF 
significantly reduced the proportion of CD38+CD8+(p=.0625; p=.003 respectively). g) Following 12 
months of cART HIV+ patients as a whole showed a significant decrease of CD38+CD45R0+CD8+ 
(p<.0001). In line with this observation, both H-CSF and L-CSF significantly reduced the proportion of 
CD38+CD45R0+CD8+ (p=.0625; p=.003; respectively). 
 
 
Figure 16 
T-cell maturation in L-CSF and H-CSF following 12 months of cART. 
Figure 4. T-cell maturation in L-CSF and H-CSF following
12 months of cART
CD4 Subset
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LEGEND 
a) In HIV+ patients as a whole we observed an increasing trend in central memory CCR7+CD45RA-CD4+ 
(p=.055). b)  H-CSF did not show any modification following cART introduction. c) L-CSF significantly 
increased the proportion of naïve CCR7+CD45RA+CD4+ (p=.044) and central memory CCR7+CD45RA-
CD4+ (p=.005). d) HIV+ as a whole displayed a significant increase of naïve CCR7+CD45RA+CD8+ 
(p=.022), and a decrease of effector memory CCR7-CD45RA-CD8+ (p=.007). e) H-CSF did not show any 
modification following cART introduction in CD8 T-cell maturation. f) L-CSF significantly increased the 
proportion of naïve CCR7+CD45RA+CD8+ (p=.005) and significantly reduced effector memory CCR7-
CD45RA-CD8+ (p=.018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 
Analysis of functionally distinct populations of HIV- and CMV-specific CD4 T-cells in L-CSF and H-CSF following 12 months of cART
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Figure 5. Analysis of functionally distinct populations of HIV- and CMV-specific CD4
T-cells in L-CSF and H-CSF following 12 months of cART
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LEGEND 
We next assessed CD4 ability to respond to HIV and CMV stimulation. We defined HIV+ patients as (i) H-CSF: CSF/plasma HIV-RNA  ratio ≥1 and (ii) L-CSF 
CSF/plasma<1. 
a) Flow cytometry profiles of the distribution of blood HIV and CMV-specific CD4 T-cells within IL-2-, IFN-ỿ- and IL-2/IFN-ỿ-secreting cell population in 
representative H-CSF and L-CSF. b) 
Data are presented as median (IQR). Following cART introduction, HIV+ patients as a whole displayed a significant reduction of IL-2+IFN-ỿ-CD4+ upon HIV exposure 
(p=.008). Interestingly, when we stratified patients according to CSF HIV-RNA levels, we observed a significant decrease in IL-2-expressing CD4 T-cells in L-CSF 
alone (p=.007), but not in H-CSF (p=.250). c) 12 months of cART resulted in a significant decrease of IL-2+IFN-ỿ-CD4+ even after CMV challenge (p=.0007) in the 
total population. Similarly, at T12 L-CSF showed a significant decrease of IL-2-expressing T-cells following CMV exposure (p=.0005). d-e) Proportion of HIV- and 
CMV-specific CD4 T cells within the different cytokine-producing cell populations in H-CSF and L-CSF, prior and after 12 months of cART. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 
Analysis of functionally distinct populations of HIV- and CMV-specific CD8 T-cells in L-CSF and H-CSF following 12 months of cART
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Figure 6. Analysis of functionally distinct populations of HIV- and CMV-specific CD8
T-cells in L-CSF and H-CSF following 12 months of cART
a) b)
c)
d) e)
 
 
LEGEND 
a) Flow cytometry profiles of the distribution of blood HIV and CMV-specific CD4 T-cells within IFN-ỿ- and IL-2/IFN-ỿ-secreting cell population in representative H-
CSF and L-CSF. b) Data are presented as median (IQR). Following cART introduction, we failed to observed significant changes in HIV-specific cytokine-producing 
CD8. c) Similarly, no major differences were observed in CMV-specific response. d-e) Proportion of HIV- and CMV-specific CD8 T cells within the different cytokine-
producing cell populations in H-CSF and L-CSF, prior and after 12 months of cART. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 
CSF markers in L-CSF and H-CSF following 12 months of cART 
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Figure 7. CSF markers in L-CSF and H-CSF following 12 months of cART
a) b) c)
d) e) f)
g)
 
LEGEND 
We next assessed the levels of cytokine/chemokine and astrocyte damage marker within the CSF following 12 month of cART. We defined HIV+ patients as (i) H-
CSF: CSF/plasma HIV-RNA  ratio ≥1 and (ii) L-CSF CSF/plasma<1. a) HIV+ as whole displayed significant reduction of sCD14 (p=.001). Similarly, L-CSF alone showed a 
significant reduction of CSF sCD14 (p=.008). b) HIV+ as a whole displayed significant reduction of IL-6 (p=.025), confirmed by L-CSF only (p=.037). c) No differences 
in CSF TNF-α levels were found. d) At T12, HIV+ as whole displayed significant reduction of MCP-1 (p=.012). Similarly, significant changes in L-CSF were noted 
(p=.017). e) HIV+ as whole displayed significant reduction of IP-10 (p=.014), not seen in H-CSF and L-CSF. f) We failed to find significant variation in neopterin 
levels. g) No significant differences in astrocyte damage marker S100beta were found in the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14 Peripheral markers in 22 patients with neurocognitive screening tests available. 
 H-CSF L-CSF 
 T0 T12 p 
values 
T0 T12 p 
values 
Peripheral Blood Markers 
CD8/38 % 12 (5-32) 2 (2,5-3,25) 0.063 15 (10-21) 2 (1,25-2) 0.005 
CD8/38/RO % 6 (4-16) 1 (1-1,25) 0.063 8,5 (5-15,25) 1 (1-1) 0.005 
DR/38/4 % 3,3 (1,02-6,85) 0,30 (1-1,87) 0.125 2,2 (1-5,3 1,35 (0,45-2,37) 0.203 
DR/38/8 % 8,35 (5,57-18,55) 2,3 (3,48-5,21) 0.25 9,3 (5,05-19,10) 3,06  (1,12-7,73) 0.16 
IL-6 pg/ml 3,5 (1,37-7,54) 1,46 (1,84-5,89) 0.812 1,30 (0,37-2,02) 1,57 (1,37-2,69) 0.461 
TNFa pg/ml 1,79 (0,56-6,10) 0,455 (0,490-0,635) 0.125 3,44 (1,29-4,73) 0,6 (0,46-0,89) 0.008 
sCD14 ug/ml 3,51 (2,64-5,26) 2,60 (3,89-4,63) 0.812 3,04 (2,58-4,14) 5,24 (2,95-5,86) 0.008 
IFN-ỿ, pg/ml 67,36 (62,67-89,81) 50,99 (59,05-74,06) 0.063 66,86 (57,32-74,65) 55,36 (45,23-62,67) 0.625 
CD4+CCR7+CD45RA+ (naive), % 1,25 (0,27-4,2) 0,45 (1,50-4,34) 1 1,65 (1,02-2,85) 3,40 (2,31-7,71) 0.079 
CD4+CCR7+CD45RA- (CM), % 2,65 (2,35-4,70) 1,65 (3,50-3,53) 0.875 4 (2,55-4,65) 4,15 (2,56-6,925) 0.104 
CD4+CCR7-CD45RA+ (TD), % 42,30 (14,68-52,68) 21,75 (32,80-52,96) 0.25 30,9 (25,3-42,7) 34,35 (28,38-46,15) 0.951 
CD4+CCR7-CD45RA- (EM), % 51,75 (42,15-82,13) 39,63 (62,2-75,65) 0.5 59 (49,75-67,90) 50,95 (41,40-58,18) 0.241 
CD8+CCR7+CD45RA+ (naive), % 1,50 (0,80-2,40) 0,95 (1,50-4,13) 0.625 1,1 (0,65-2,40) 4,6 (1,47-16,49) 0.011 
CD8+CCR7+CD45RA- (CM), % 1,5 (0,8-2,1) 0,64 (1,30-1,65) 0.312 1,4 (1,05-1,95) 1,09 (0,85-1,71) 0.626 
CD8+CCR7-CD45RA+ (TD), % 32,10 (26,90-48,70) 33,26 (45,10-53,60) 0.312 40,50 (29,75-47,10) 53,30 (35,47-60,28) 0.209 
CD8+CCR7-CD45RA- (EM), % 64,90 (49,70-70,30) 43,65 (51,01-62,75) 0.312 54,60 (48,70-67,25) 42,80 (31,37-48,25) 0.035 
HIV-specific T-cell Response, Median (IQR) 
CD4+IL2+IFNỿ+, % 0,0 (0,0-0,07) 0,0 (0,0-0,0) 1 0,0 (0,0-0,0) 0,0 (0,0-0,03) 0.625 
CD4+IL2+IFNỿ-, % 0,90 (0,52-1,42) 0,10 (0,05-0,70) 0.62 0,75 (0,025-1,89) 0,0 (0,0-0,11) 0.007 
CD4+IL2-IFNỿ+, % 0,20 (0,0-0,50) 0,30 (0,10-0,50) 0.173 0,0 (0,0-0,57) 0,05 (0,0-0,15) 1 
CD8+IL2+IFNỿ+, % 0,10 (0,0-0,20) 0,01 (0,0-0,06) 0.25 0,0 (0,0-0,10) 0,0 (0,0-0,015) 0.136 
CD8+IL2-IFNỿ+, % 0,10 (0,0-0,40) 0,10 (0,0-2,70) 0.7518 0,0 (0,0-0,11) 0,06 (0,0-0,17) 1 
CMV-specific T-cell Response, Median (IQR) 
CD4+IL2+IFNỿ+, % 0,0 (0,0-0,15) 0,0 (0,0-0,0) 1 0,0 (0,0-0,10) 0,0 (0,0-0,002) 0.625 
CD4+IL2+IFNỿ-, % 2,0 (1,30-3,30) 0,20 (0,0-1,00) 0.174 0,66 (0,12-2,1) 0,05 (0,0-0,53) 0.0005 
CD4+IL2-IFNỿ+, % 0,50 (0,07-0,85) 0,55 (0,0-1,10) 0.197 0,40 (0,0-0,73) 0,34 (0,15-1,57) 0.812 
CD8+IL2+IFNỿ+, % 0,0 (0,0-0,10) 0,0 (0,0-0,11) 0.875 0,0 (0,0-0,09) 0,0 (0,0-0,09) 0.752 
CD8+IL2-IFNỿ+, % 0,20 (0,0-0,80) 1,0 (0,0-1,30) 1 0,0 (0,0-0,23) 0,12 (0,0-1,42) 0.625 
Table 15 
CSF markers in 22 patients with neurocognitive screening tests available. 
 
 H-CSF L-CSF 
 T0 T12 p 
values 
T0 T12 p 
values 
CSF soluble markers 
sCD14 (ng/ml) 932,5 (670,3-1195) 208 (137-294) 0.25 270,5 (197,3-353,3) 165,5 (116,3-202) 0.125 
IL6 (pg/ml) 1,56 (0,59-2,079 0,59 (0,33-0,59) 0.057 0,59 (0,50-1,31) 0,50 (0,33-0,68) 0.125 
TNF-α (pg/ml) 1,17 (0,78-2,16) 0,63 (0,47-0,78) 0.063 0,94 (0,745-1,015) 0,78 (0,63-0,94) 0.875 
MCP-1 (ng/ml) 1,51 (0,93-1,52) 0,74 (0,53-0,77) 0.063 0,86 (0,735-1,15) 0,61 (0,49-0,73) 0.031 
IP-10 (ng/ml) 1,87 (1,34-2,41) 0,25 (0,19-0,37) 0.125 0,585 (0,36-0,99) 0,22 (0,17-0,32) 0.031 
S100BETA 321 (170-365) 298 (69-337) 0.5 290 (183-406) 251,5 (136,8-365,3) 0.547 
Neopterin 0,80 (0,0-4,15) 0,35 (0,13-0,61) 0.625 1,15 (0,79-1,35) 0,73 (0,48-0,88) 0.207 
 
 
LEGEND 
All data are median (IQR). Statistical analyses: Mann-Whitney U Test. IQR: Interquartile range; CSF: cerebrospinal fluid; H-CSF: High cerebrospinal fluid (CSF/plasma 
HIV-RNA ≥1); L-CSF: Low cerebrospinal fluid (CSF/plasma HIV-RNA<1).CM: central memory, EM: effector memory, TD: terminally differentiated. 
 
 
 
 
 
 
 
 
 
 
Table 16 
Patients’ neurocognitive performances at T0 and T1. 
 
PATIENT 1 RAW SCORE 
(T0) 
EQUIVALENT 
SCORE (T0) 
RAW SCORE 
(T1) 
EQUIVALENT 
SCORE (T1) 
     
Digit Span Test 
direct/reverse 
3/3 0/0 7/4 4/1 
Rey Auditory Verbal 
Learning Test/ recalling 
41/7 4/3 48/7 4/3 
Trial making test A/B 26.5/106.48 4/4 38/91.09 4/4 
Trial making test B-A 79.98 4 53.09 4 
Symbol Digit Modality 
Test 
38 2 43 2 
Finger tapping test 
right/left 
40.6/30.2 0/0 42.8/39.8 0/0 
Fluency test 
(phonemic)/(semantic) 
23/50 2/4 33/47 4/4 
Stroop Color Word 
Interference Test 
(time)/error 
31.58/1 2/3 20.15/1.5 4/3 
PATIENT 2 RAW SCORE 
(T0) 
EQUIVALENT 
SCORE (T0) 
RAW SCORE 
(T1) 
EQUIVALENT 
SCORE (T1) 
Digit Span Test 
direct/reverse 
8/8 4/4 7/5 4/2 
Rey Auditory Verbal 
Learning Test/recalling 
46/5 3/0 57/7 4/1 
Trial making test A/B 27.12/50.62 4/4 20.76/58.23 4/4 
Trial making test B-A 23.5 4 37.47 4 
Symbol Digit Modality 
Test 
59 2 66 2 
Finger tapping test 
right/left 
63.4/51.4 >1/>1 58.2/46.6 >1/>1 
Fluency test (phonemic)/ 
(semantic) 
48/62 4/4 32/63 3/4 
Stroop Color Word 
Interference Test (time)/ 
(error) 
15/3 2/0 9.71/0 4/3 
PATIENT 3 
 
 RAW SCORE 
(T0) 
EQUIVALENT 
SCORE (T0) 
RAW SCORE 
(T1) 
EQUIVALENT 
SCORE (T1) 
Digit Span Test 
direct/reverse 
4/4 1/1 6/4 4/1 
Rey Auditory Verbal 
Learning Test/ recalling 
44/10 3/3 47/7 4/1 
Trial making test A/B 39,32/139.56 4/3 32.56/60.37 4/4 
Trial making test B-A 100,24 2 27.81 4 
117 
 
Symbol Digit Modality 
Test 
29 0 26 0 
Finger tapping test 
right/left 
39.2/46 0/0 43.8/52 >1/>1 
Fluency test (phonemic)/ 
(semantic) 
30/48 3/4 20/43 1/4 
Stroop Color Word 
Interference Test 
(time)/(error) 
23.9/7 2/0 12.5/0 4/3 
 
LEGEND 
Equivalent score: 0= pathologic, ≥1=normal. T0, baseline, T1, end of the rehabilitation program. 
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Table 17 
Functional assessment for each patient. 
 
PATIENT 1 SCORE AT T0 SCORE AT T1 
IADL 7 8 
HADS A/D 12/3 7/1 
SF-36 PHI/MHI 1/0 1/0 
PATIENT 2 SCORE AT T0 SCORE AT T1 
IADL 8 8 
HADS A/D 1/0 0/0 
SF-36 PHI/MHI 0/0 0/0 
PATIENT 3 SCORE AT T0 SCORE AT T1 
IADL 7 8 
HADS A/D 9/10 5/11 
SF-36 PHI/MHI 0/1 0/0 
 
LEGEND 
IADL altered if <8, HADS A altered if ≥12, HADS D altered if≥12, SF-36 PHI and MHI altered if 1. HADS 
A=anxiety score; HADS D=depression score; SF-36 PSS= physical health index; SF-36 MSS= mental health 
index.  
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